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ABSTRACT 
 Multiple sclerosis (MS) is a chronic central nervous system disease 
featuring exacerbations of inflammation and demyelination that cause 
progressively debilitating clinical effects over time. Current treatments for multiple 
sclerosis are limited in their ability to impact overall disease progression. 
Research aimed at generation of novel potential therapeutics for MS is needed. 
Recently, kallikrein 6 (KLK6),  a member of the kallikrein (KLK) family of secreted 
serine proteases, was found to be elevated in the cerebrospinal fluid and brain of 
MS patients. The fifteen known tissue-based KLKs cleave proteins through a 
similar mechanism, but have different binding pocket specificity, diverse 
localization in human tissues, and multiple biological functions. KLKs have been 
linked to normal human physiology (e.g. KLK4, enamel formation) and disease 
(e.g. KLK3, prostate cancer). KLK6 is one of the highest expressed serine 
proteases in the healthy human brain and is expressed predominately in mature 
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oligodendrocytes in both human and mouse brain. The role of KLK6 in 
oligodendrocyte maturation, myelination, and disease is not fully understood.  
 To evaluate the role of KLK6 in oligodendrocyte maturation, I used a 
pluripotent in vitro primary cell system to assess the impact of exogenous KLK6 
and modulators of the KLK6 pathway on oligodendrocyte maturation. I 
demonstrate that signaling through KLK6 decreases the number of mature 
oligodendrocytes in culture, whereas blockade of KLK6 signaling increases the 
number of mature oligodendrocytes in culture in the presence of triiodothyronine 
higher than either agent alone. This work suggests that KLK6 modulation impacts 
oligodendrocyte maturation. To understand the potential impact of KLK6 pathway 
inhibition on remyelination, I used the toxin cuprizone to induce demyelination in 
mice. I found that animals treated with a KLK6 inhibitor had increased myelin 
staining in the corpus callosum compared to vehicle-treated. This work suggests 
that KLK6 modulates oligodendrocyte maturation and myelination and may be 
relevant for improving myelin-related therapeutic outcomes, particularly in 
multiple sclerosis.  
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CHAPTER ONE 
Introduction 
Multiple Sclerosis 
 Multiple sclerosis (MS) is a chronic, auto-immune disorder of the central 
nervous system that can lead to lack of coordinated muscle movements, fatigue, 
decreased cognition, impaired vision, paralysis, and depression (Ben-Zacharia, 
2011). MS is typically diagnosed between the ages of 20-40 years old and affects 
double the number of women compared to men; the overall prevalence of MS is 
estimated to be over 2.3 million people (Ransohoff et al., 2015). The etiology of 
MS is currently unknown and thus the disease is likely to be due to multiple 
factors, such as genetics and environment.  
 Genetic polymorphisms in human leukocyte antigen (HLA) genes that 
regulate major histocompatibility complex (MHC) proteins which in turn modulate 
immune responses have been shown to be either protective or act as risk factors 
for MS (Moutsianas et al., 2015). One environmental risk factor to developing MS 
is thought to be lack of exposure to sunlight and/or low vitamin D levels (Pierrot-
Deseilligny and Souberbielle, 2017). Prevalence of MS has been inversely 
associated with the angular distance from latitudes such as those near the 
equator that experience almost continuous sun exposure/ultraviolet light radiation 
(Sloka et al., 2011). Further, single nucleotide polymorphisms associated with 
vitamin D absorption have been implicated in MS genome-wide association 
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studies (International Multiple Sclerosis Genetics et al., 2011). It is hypothesized 
that the association between vitamin D levels and multiple sclerosis may be that 
vitamin D is helpful in control of excessive T-cell mediated responses (Cantorna 
and Waddell, 2014). 
 While the mechanisms behind what triggers MS are still unknown, excess 
inflammation is a significant contributor to pathology in MS. Peripheral T 
lymphocytes and macrophages infiltrate into the central nervous system and 
direct damage of the myelin sheath. Myelin sheaths are present on neurons in a 
variety of areas throughout the central nervous system, but they are especially 
noticeable grossly when they travel in large groupings such as tracts or funiculi- 
areas commonly collectively called “white matter” within the brain or spinal cord. 
Focal areas of damage to the myelin sheath in such areas where it is normally 
abundant are referred to as lesions or plaques. This damage prevents rapid 
conduction of neuronal action potentials and leaves underlying neuronal axons 
more vulnerable to degeneration (Dendrou et al., 2015). 
  Other neurodegenerative disorders such as Alzheimer’s disease and 
Parkinson’s disease have a characteristically-defined anatomical localization of 
pathology (AD: neurofibrillary tangle associated; PD: Lewy body associated) as 
disease severity increases (Braak et al., 2003; Braak et al., 2006).  Multiple 
sclerosis does not have a defined anatomical localization of plaque progression 
as severity of disease increases. However, the most frequent area of incidence 
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of plaques in MS patient gray matter is in cortical sulci (invaginations of cortical 
tissue, below the pia mater) (Haider et al., 2016). The most frequent area of 
incidence of plaques in white matter of MS patients is in periventricular locations, 
or in white matter areas that border the ventricular system of the brain that 
circulates cerebrospinal fluid (Haider et al., 2016). Plaques can also be present in 
gray and white matter of spinal cord in MS, but plaques in the brain are generally 
more common at earlier stages of disease (Kearney et al., 2015a; Kearney et al., 
2015b). Less than 10% of MS patients are estimated to have spinal cord plaques 
only (Nociti et al., 2005). However, magnetic resonance imaging (MRI) to confirm 
diagnosis and progression in MS clinical trials typically focuses on brain lesions 
instead of spinal cord due to ease of imaging relative to current technological 
methods and structure size (Kearney et al., 2015a; Muccilli et al., 2018).  
 White matter plaques are visible by both MRI methods and histological 
techniques. Gray matter or cortical plaques are more visible by histological 
techniques than by MRI, although a recent study reported moderate success with 
cortical plaque detection using 7 Tesla magnetic resonance scanners (versus 1.5 
T scanner) (Kilsdonk et al., 2016). Compared to white matter plaques, gray 
matter plaques are more correlated to clinical symptom severity in patients, and 
this is thought to be because these areas may progress to neuronal atrophy and 
degeneration more rapidly (Calabrese et al., 2011; Kilsdonk et al., 2016; 
Bergsland et al., 2018). 
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 There are four clinical subtypes of MS: 1) relapsing-remitting (RRMS), 2) 
secondary progressive (SPMS), 3) primary-progressive (PPMS), and 4) 
progressive-relapsing (PRMS). The clinical subtypes are largely defined by their 
manifestation of behavioral symptoms, although presentation of disease-related 
symptoms is still quite heterogeneous within each subtype. RRMS is the most 
common clinical subtype of MS. RRMS alternates between periods of symptoms 
(relapses) followed by some degree of remission. It has been shown that 
although symptoms may improve in remission, damaged myelin is still present 
(Stadelmann and Bruck, 2008). There is an approximate 80% conversion rate 
from RRMS into SPMS, which results in an overall deteriorating condition that 
includes neuronal damage in addition to myelin damage (Dendrou et al., 2015). 
Although the slope of increasing disability can differ, PPMS is defined by an 
almost linear progression of disease worsening without remission. PRMS is the 
least common form of MS and is characterized by a gradual worsening of overall 
condition with periods of exacerbated symptoms but no remissions. The 
progressive forms of MS demonstrate less remyelination and more demyelination 
than RRMS (Stadelmann and Bruck, 2008).    
 There is still ongoing discussion among experts of whether these clinical 
subtypes reflect disease heterogeneity due to other factors or if MS is a disease 
with discrete sequential stages of pathology. While it is generally accepted that 
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relapsing patients can become progressive; it is not clear if all progressive MS 
cases started as relapsing-remitting MS cases (Kuchling et al., 2014). Diagnosis 
of MS relies heavily on clinical assessment, medical history, and an important 
criteria that the symptoms are not explained by any other known cause (Katz 
Sand, 2015; Thompson et al., 2017). There are no definite diagnostic biomarkers 
of MS or its subtypes, although measurement of white matter using T2 MRI (with 
or without gadolinium-enhanced contrast imaging) is usually done to confirm 
incidence of multiple lesions in different regions of the CNS (Katz Sand, 2015; 
Siva, 2018). Further, the presence of immunoglobulins (IgGs) in cerebrospinal 
fluid; particularly oligoclonal bands in CSF that are not in serum can be used to 
confirm a diagnosis combined with medical history and imaging but they are not 
exclusive to MS (Winger and Zamvil, 2016; Thompson et al., 2017). Historically it 
has been thought that CSF-specific IgGs were predominately to myelin proteins 
in MS patients, but recent evidence has suggested they can also be to 
intracellular proteins more indicative of general cellular debris resulting from cell 
death (Winger and Zamvil, 2016). 
 Several therapeutics are currently approved to decrease inflammation in 
MS, but none are able to restore myelin once it has been damaged (Ransohoff et 
al., 2015). At this time, there are more therapeutics available for one specific 
clinical subtype of MS (relapsing-remitting, RRMS) than the other clinical 
subtypes. The main therapeutic benefit of these treatments is a reduction in 
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symptoms and length of type in “relapse” phase of RRMS. RRMS is often the 
presenting form or earliest phase of MS which may enable therapeutic 
intervention to be more successful by introducing it before endogenous repair 
mechanisms are no longer effective and neuronal death occurs (Dargahi et al., 
2017).   
 The first pharmacological therapy approved in the United States by the 
Food and Drug Administration (FDA) was interferon beta-1b injectable Betaseron 
(Bayer) in 1993 (Ransohoff et al., 2015; Auricchio et al., 2017). Several other 
interferon beta-based treatments followed.  The exact mechanism by which 
interferon beta is able to decrease MRI white matter lesions is an area of ongoing 
investigation, but generally, interferons are cytokines which regulate anti-
inflammatory and pro-inflammatory signaling (Kieseier, 2011; Ransohoff et al., 
2015; Haji Abdolvahab et al., 2016; Auricchio et al., 2017). Interferon beta 
treatments are still used today, due to their moderate efficacy and reasonable 
safety profile, however they are not effective for all patients and there is limited 
ability to predetermine those who would best benefit beforehand (Ottoboni et al., 
2012; Ransohoff et al., 2015). 
 Several effective therapeutics in MS that were more recently developed 
are also anti-inflammatory. These include Natalizumab (Tysabri, 2004, 
Elan/Biogen) and Fingolimod (Gilenya, 2010, Novartis, first oral MS treatment), 
and Dimethyl fumarate (Tecfidera, 2013, Biogen). Natalizumab and Fingolimod 
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both decrease T cell infiltration into the CNS by targeting integrin-alpha4 or the 
sphingosine-1-phosphate receptor, respectively (Ransohoff et al., 2015). 
Dimethyl fumarate reduces inflammation and oxidative stress by activating 
nuclear factor (erythroid-derived 2)-like-2 (NRF2) to stabilize NADPH:quinolone 
oxidoreductase1, as well as potentially through additional indirect pathways 
which are still being clarified (Linker and Gold, 2013; Brennan et al., 2016; 
Ghadiri et al., 2017). All of these new drugs have potentially serious side effects 
which include risk of  progressive multifocal leukoencephalopathy (PML; 
Natalizumab, Dimethyl fumarate) as well as herpes zoster or cardiac 
complications (Fingolimod) (Ransohoff et al., 2015; Auricchio et al., 2017). 
Immunosuppression causes dormant JC polyomavirus present in a number of 
adults to convert to PML, which can be fatal (Williamson and Berger, 2017). 
The most recent treatment to receive FDA approval for MS is also the first ever 
approval for the PPMS subtype of MS. Ocrelizumab (Ocrevus, 2017, 
Roche/Genentech) is approved for both PPMS and RRMS due to arms of the 
clinical trial being run for both MS subtypes concurrently (Jakimovski et al., 2017; 
Stahnke and Holt, 2017). Ocrelizumab is an anti-inflammatory that works by 
depleting B cells and thus may reduce increased IgG as well in patients (Winger 
and Zamvil, 2016; Stahnke and Holt, 2017). Efficacy was shown in terms of 
reduced clinical disability progression at 12 weeks compared to placebo in PPMS 
(Stahnke and Holt, 2017). Side effects are still being evaluated, but there was an 
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increase in infections (the one PML case was confounded due to the patient 
being on natalizumab just prior to study) and breast cancer in the treatment 
group compared to placebo (Stahnke and Holt, 2017). 
 Ongoing areas of research in treatment for MS include multipotent 
hematopoietic stem cell transplantation (Dargahi et al., 2017; Muraro et al., 
2017), other immunomodulation techniques (Dargahi et al., 2017), and, the focus 
of this dissertation, understanding mechanisms of myelin generation and repair 
(Domingues et al., 2016; Akkermann et al., 2017; Cole et al., 2017). 
 
Oligodendrocyte maturation and myelination 
 Oligodendrocyte (OL) processes insulate neuronal axons with myelin in 
the central nervous system which triggers sodium channel consolidation at nodes 
of Ranvier (where myelin is not present) and increases conduction velocity of 
action potentials (Bradl and Lassmann, 2009). In addition, the myelination of 
neuronal axons by OL processes creates a physical barrier of protection to the 
ensheathed neurons and also provides trophic support for axonal integrity 
(Crawford et al., 2013; Schultz et al., 2017).  
 OLs in the mammalian forebrain derive embryonically first from neural 
stem cells in the medial ganglionic eminence. Later, a second cohort is derived 
from the lateral and caudal ganglionic eminences. After parturition, a third cohort 
is derived from the cortex (Baumann and Pham-Dinh, 2001). It has been shown 
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that if one group does not occur, another can take its place without disturbance in 
the developing brain (Jakovcevski and Zecevic, 2005a, b; Kessaris et al., 2006). 
 The maturation of OLs from neural precursor cells has been characterized 
well in terms of morphology and molecular identifiers (Nishiyama et al., 2009). 
Oligodendrocyte precursor cells (OPCs), which precede OLs in cell lineage, are 
different from OLs in terms of function as well as structure. OPCs are capable of 
proliferation and migration, even in adult mammals (Purger et al., 2016).  
Migration of OPCs is dependent on signals such as extracellular matrix proteins, 
plate-derived growth factor, and semaphorins (Bradl and Lassmann, 2009).  
 Once in location, OPCs processes make contact with axons through cell-
adhesion molecules, then ensheath the axons as they differentiate to myelinating 
OLs (Purger et al., 2016). Oligodendrocytes undergo normal turnover in the 
brain. It has been reported that the average rate of oligodendrocyte maturation in 
the corpus callosum of humans is about one out of 300 cells per year (~0.32%) 
after age 5 (Yeung et al., 2014). The average number of oligodendrocytes in the 
normal adult human corpus callosum is estimated to be between 4.0 x 109 and 
5.0 x 109 (Yeung et al., 2014). 
 OLs differ from the myelinating cells of the peripheral nervous system in 
several ways, most notably in their myelin protein composition and number of 
axons that a single cell can myelinate (Nave and Werner, 2014; Feltri et al., 
2016; Herbert and Monk, 2017). Schwann cells, the myelinating cells of the 
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peripheral nervous system, only wrap myelin around one axon (Feltri et al., 
2016). A single oligodendrocyte can wrap myelin around as many as forty axons 
(Miron et al., 2011). Schwann cells also have a layer of cytoplasm surrounding 
the myelinated layer of axon, while the most external facing component of a 
myelinating oligodendrocyte is the major dense line of its membrane (Peters, 
1960).  
 The myelinated OL-axon complex is structurally intricate. Myelin proteins, 
such as myelin basic protein (MBP), help tighten layers of wrapped myelin 
around an axon at the internode, forming compact myelin in order to increase 
capacitance (Lee et al., 2014; Simons and Nave, 2015; Zuchero et al., 2015). 
Next to the internode is the juxtaparanode which is also under compact myelin 
but is notable as the part of an axon where potassium channels that establish 
resting potential are congregated. The paranode lies between the potassium 
channel cluster and the unmyelinated node of Ranvier sodium channel cluster 
segment to allow for efficient depolarization and repolarization. The paranode 
primarily contains structural proteins (e.g. contactin and contactin-associated 
protein) that connect the OL plasma membrane to the axon laterally in an area 
without compact myelin (Poliak and Peles, 2003; Buttermore et al., 2013). 
 Despite the importance of the myelin proteins in proper myelin function, 
myelin is predominately composed of lipids. The major types of lipids that 
compose myelin are: cholesterol, phospholipids (plasmalogens, 
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phosphatidylethanolamine, phosphatidylcholine), and glycosphingolipids 
(galactocerebrosides / gatactosylceramides, fast migrating cerebrosides, and 
gangliosides) (Podbielska et al., 2013). Synthesis of lipid-rich myelin by 
oligodendrocytes is dependent on astrocytes and to a lesser degree, dietary 
lipids, as demonstrated by a recent study where genetic deletion of a coactivator 
required for lipid biosynthesis was targeted in either oligodendrocytes and/or 
astrocytes (Camargo et al., 2017). Typically, cholesterol required by the CNS is 
made within the CNS due to the blood-brain barrier (Kiray et al., 2016). 
 The process of myelination in the brain is not limited to development. Adult 
mammalian brains are capable of “re-myelination” of damaged areas of myelin 
(Peters and Sethares, 2003). When the myelin sheath surrounding an axon 
becomes damaged, OPCs migrate and proliferate at the site of injury in response 
to secreted factors and/or neuronal electrical activity where they differentiate into 
mature oligodendrocytes that will engage in remyelination in that area (Barres 
and Raff, 1993; Demerens et al., 1996; Crawford et al., 2013). Remyelination is 
more easily observed on larger axons. Remyelinated axons, or axons with newly-
wrapped myelin, are discernable due to the fewer layers of myelin around these 
axons compared to those in which myelin was laid down during development 
(Franklin and Ffrench-Constant, 2017). Limited longitudinal studies exist that 
characterize remyelination but there is some evidence to suggest that myelin will 
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generate more layers with time and look indistinguishable from myelin from 
development origin (Powers et al., 2013; Bercury and Macklin, 2015). 
 The initiation and regulation of myelination is impacted both by neurons 
and OLs directly involved in the process as well as from indirect signaling 
pathways from a variety of sources. For example, axons that are not permissive 
to myelination secrete or express inhibitory proteins (e.g. LINGO-1, PSA-NCAM, 
Jagged/Notch, Wnt) to prevent maturation of OPCs to OLs temporally or spatially 
(Emery, 2010; Franklin and Ffrench-Constant, 2017). Axon diameter has also 
been correlated with OL myelination propensity (Lee et al., 2012). It has also 
been shown that “fully” mature OLs are less likely to myelinate axons than 
recently differentiated OLs (Watkins et al., 2008). Similarly, mature 
oligodendrocytes, myelin, or myelin debris can have a negative feedback 
relationship by inhibiting additional OPCs in the local environment from maturing 
to OLs (Kotter et al., 2006; Plemel et al., 2013). Calcium-signaling has been 
shown to be a mechanism with diverse upstream initiation pathways that 
modulates myelin in different ways: temporally shorter, lower amplitude calcium 
bursts stabilize myelin formation while higher amplitude, longer calcium bursts 
cause myelin retraction (Baraban et al., 2018). 
 Environmental stimuli are capable of altering the volume of myelinated 
neuronal fibers. For example, social isolation can decrease the volume of white 
matter (Liu et al., 2012; Makinodan et al., 2012) while plasticity of learning a new 
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task can elevate myelination in brain regions associated with conducting that task 
(Scholz et al., 2009; Sampaio-Baptista et al., 2013).  
 The normal process of aging also has an impact on myelin structure and 
volume. At the electron microscopy level, aging can cause areas of dense 
cytoplasm in oligodendrocytes, which is thought to lead to degeneration, due to 
splitting of the major dense line (Peters, 2002). It also can create “bubbles” of 
fluid that disturb the intraperiod lines which causes distension of myelin 
surrounding an axon and is also expected to lead to degeneration (Peters, 2002). 
Also occurring with age is “redundant” myelin that myelinates above what is 
typical for the axon diameter. This can also lead to a phenomenon where the 
excessive myelination around the axon splits into two compact bundles of myelin 
separated by a gap (Peters, 2002).   
  Increased ventricular space, which has been correlated with decreased 
white matter volume, is also associated with aging (Guttmann et al., 1998; Coutu 
et al., 2016). Evidence from recent studies suggests that decreased vascular 
perfusion of the brain could be a factor leading to increased white matter 
pathology in aging. Using cerebral blood flow, cerebrovascular reactivity 
measurements, white matter structural measures (by diffusion tensor imaging-
mean diffusivity or fractional anisotropy, and fluid attenuated inversion recovery 
using magnetic resonance imaging) it has been shown that hypoperfusion of the 
brain precedes white matter hyperintensities indicative of pathology; 
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periventricular areas especially demonstrated hypoperfusion (Promjunyakul et 
al., 2016; Sam et al., 2016).  In disease state, these normal biological events 
could compound the severity of pathology. For example, periventricular regions 
are also a frequent area of demyelinated plaques in MS (Haider et al., 2016). In 
addition, cardiovascular risk factors such as smoking and hypertension have 
been shown to increase demyelinated plaque area in MS (Kappus et al., 2016). 
 
Serine Proteases 
 Human proteases are largely classified into families based on mechanism 
in which they cleave proteins. Several depend on involvement of a particular 
amino acid and thus are named after said amino acid: aspartic proteases, 
cysteine proteases, threonine proteases, and serine proteases. Another group is 
classified based on requirement of a metal ion to cleave proteins: 
metalloproteases.  
 Serine proteases are one the largest families of human proteases, making 
up about twenty-five percent of all known proteases (Di Cera, 2009; Prassas et 
al., 2015). Serine proteases are involved in a diverse array of biological 
processes that span from regulation of immunological complement cascades 
(Bajic et al., 2015), apoptosis (Trapani, 2001), increasing the epithelial barrier in 
the intestine (Ronaghan et al., 2016),  and aiding in iron absorption (Ramsay et 
al., 2009). The most well-known serine proteases are perhaps thrombin, trypsin 
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and chymotrypsin. In wound healing, prothrombin is cleaved to become the 
active enzyme thrombin. Thrombin cleaves fibrinogen to fibrin which allows for 
the formation of an insoluble clot to stop bleeding (Weisel and Litvinov, 2017). 
Trypsin and chymotrypsin are digestive serine proteases that are made in 
zymogen form in the pancreas (trypsinogen and chymotrypsinogen) that are 
activated in the small intestine to break down food so nutrients can be absorbed 
(Whitcomb and Lowe, 2007). Trypsin is also commonly used in a research 
laboratory setting to detach adherent cells in cell culture and chop up proteins for 
proteomic analysis (Brown et al., 2007; Vandermarliere et al., 2013). 
 Serine proteases cleave proteins through a well-defined biochemical 
reaction using a highly conserved “catalytic triad” which is the active site of the 
enzymes. The canonical catalytic triad is composed of three highly conserved 
amino acids: serine, aspartic acid, and histidine. The major proteolytic 
component of the catalytic triad is the hydroxyl group of the serine that cleaves 
the substrate amino acid at the carbonyl group through a nucleophilic attack 
mechanism. The aspartic acid and histidine form a hydrogen bond which 
stabilizes the reaction by creating a stronger nucleophile by making the histidine 
more basic (Di Cera, 2009). Serine proteases can be further divided into 
subcategories: chymotrypsins, elastases, kallikreins, matriptases, thrombins, 
trypsins, and tryptases. These subcategories are largely driven by the binding 
pocket size and specificity and types of typical substrates. Serine protease 
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activity is regulated post-transcriptionally. They are secreted as zymogens 
(inactive precursors which require cleavage to become active), and their activity 
also depends on pH, metal ions, serpins (serine protease inhibitors), and whether 
they can self-activate or self-terminate activity through their own cleavage 
(Prassas et al., 2015).  
   
Introduction & Approach to Dissertation 
  Recent work has demonstrated that a serine protease, Kallikrein 6 (KLK6; 
also known as protease M, neurosin, zyme, or myelencephalon-specific 
protease), is expressed specifically in OPCs/OLs in both rodent and human cells 
of the brain (Zhang et al., 2014; Bennett et al., 2016; Zhang et al., 2016). In 
addition, KLK6 levels have been shown to be elevated in MS patient brain 
(Scarisbrick et al., 2002), cerebrospinal fluid (Hebb et al., 2010), and serum 
(Scarisbrick et al., 2008) compared to control. The role of KLK6 in normal 
oligodendrocyte biology and in pathological conditions such as MS is unknown. 
 In order to elucidate the role of the serine protease KLK6 in these 
contexts, the aims of this research were threefold. First, I sought to characterize 
levels of KLK6 over oligodendrocyte maturation. To do this, I evaluated 
expression levels of KLK6 in OL maturation using rodent primary neurosphere-
derived cells and gene expression methods. Second, I sought to determine the 
consequences of KLK6 modulation on oligodendrocyte maturation and 
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myelination. To determine the consequences of KLK6 pathway activation and 
inhibition on maturation of OLs and myelination in the brain, I applied exogenous 
KLK6 pathway modulators to primary oligodendrocytes in vivo or in a cuprizone 
mouse model of corpus callosum demyelination. Third, I sought to develop 
further understanding of KLK6 expression in the human CNS and in MS patients. 
To do this, gene expression of KLK6 was evaluated in a large adult human tissue 
RNA sequencing dataset. Further, expression of KLK6 in multiple sclerosis 
patient post-mortem brain was characterized using immunohistochemistry. 
 Identifying and clarifying the pathways that regulate the maturation of 
oligodendrocytes (OLs) and myelination is important for developing therapeutics 
that promote remyelination in the context of multiple sclerosis (MS) and other 
demyelinating diseases. 
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CHAPTER TWO 
Kallikrein 6 in Oligodendrocyte Maturation 
a) Introduction 
i. Overview of Diverse Biological Functions of the Kallikrein Family of Serine 
Proteases 
 The kallikrein (KLK) family of serine proteases has fifteen known secreted 
tissue kallikrein members. Several members of the KLK family have unique 
biological functions, while others are yet unknown. KLK1 is involved in normal 
physiological functions of lung (airway mucus secretion) and kidney (normal 
tubule transporter activity). KLK2 (human glandular), and KLK3 (prostate-specific 
antigen) are expressed in prostate tissue and are a normal component of seminal 
fluid and their levels can serve as a biomarker of prostate cancer. KLK4 
(prostase or enamel-matrix protease 1) is involved in normal dental enamel 
formation. KLK5 (stratum corneum tryptic enzyme), KLK7 (stratum corneum 
enzyme or chymotryptic enzyme), and KLK10 (normal epithelial-cell-specific 1 
protein) are involved in skin desquamation and skin disorders like rosacea. Less 
is known about the biological functions of KLK6 (also known as protease M, 
neurosin, zyme, or myelencephalon-specific protease), KLK8 (neuropsin or 
ovasin), KLK9, KLK11 (hippostatin), KLK12, KLK13, KLK14, and KLK15 
(prostinogen). (Prassas et al., 2015) 
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ii. Kallikrein 6 Structure and Function 
 Recently, a large effort was undertaken to profile primary cells of the 
mouse and human brain in their basal state by RNAseq using specific antibody 
immunopanning (Zhang et al., 2014; Bennett et al., 2016; Zhang et al., 2016). 
Neurons, astrocytes, microglia, oligodendrocyte precursor cells, and 
oligodendrocytes were examined. KLK6 mRNA expression was determined to be 
specific to OPCs/OLs in the brain of both species (Zhang et al., 2014; Bennett et 
al., 2016; Zhang et al., 2016).  
 The human gene KLK6 (Entrez: 5653; Ensembl: ENSG00000167755) is at 
chromosomal location 19q13.3, is 10,483 base pairs long, and contains seven 
exons (Yousef and Diamandis, 2001). The human protein KLK6 (UniProt: 
Q92876, hK6) is 244 amino acids long, including a 16 amino acid N-terminal 
signaling component and a five amino acid pro-peptide that must be cleaved to 
activate the enzyme (Yousef et al., 1999). 
 KLK6 knockout animals are slower to develop oligodendrocytes but adults 
have a similar number compared to wildtype (Murakami et al., 2013), suggesting 
a role for KLK6 in OL development. These animals also have thinner epidermal 
cells and reduced keratinocyte proliferation than wildtype (Kishibe et al., 2016). 
The precise role of KLK6 in normal oligodendrocyte development, maturation, 
and function is unknown.  
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 Compared to the other members of the KLK family, the binding pocket of 
KLK6 has been shown to favor binding of proteins with basic amino acids 
(Prassas et al., 2015). Myelin basic protein, a protein rich in basic amino acids 
and a key protein present in OLs and CNS myelination, has been shown to be a 
substrate of KLK6 (Blaber et al., 2002; Magklara et al., 2003; Sharma et al., 
2008; Silva et al., 2017). This provides evidence that KLK6 may have a role in 
mechanisms related to myelination of neuronal axons by OLs. 
 In patients with multiple sclerosis, an auto-immune neurodegenerative 
disease that exhibits loss of CNS myelination and OLs, KLK6 levels are elevated 
in brain (Scarisbrick et al., 2002), cerebrospinal fluid (Hebb et al., 2010), and 
serum (Scarisbrick et al., 2008) compared to control samples. The role of KLK6 
in pathological conditions with abnormal oligodendrocytes and/or myelination, 
such as multiple sclerosis, is unknown. 
 Like other serine proteases, KLK6 is secreted in zymogen form and needs 
to be cleaved to become active. It can both activate and deactivate its own 
enzymatic activity through auto-cleavage events, although this action may be 
more favorably achieved through a different protease. (Blaber et al., 2007; 
Prassas et al., 2015) 
 Exogenously added KLK6 in vitro has been shown to reduce branching of 
primary rodent OLs, but to have largely no impact on OPCs (Burda et al., 2013). 
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As previously mentioned, MBP is a direct substrate of KLK6 which is present in 
OLs but not OPCs.  
 Other substrates of KLK6 can cause signaling cascades triggering indirect 
downstream consequences of KLK6 activity. A few KLK family members, 
including KLK6, have been shown to regulate proteinase-activated receptor 
(PAR) activation (Oikonomopoulou et al., 2006a; Oikonomopoulou et al., 2006b; 
Burda et al., 2013). There are four known PARs [proteins: PAR1-4; 
corresponding to genes F2R, F2RL1-3, respectively] (Noorbakhsh et al., 2003). 
PAR1 is a tethered ligand G-protein coupled receptor, where cleavage of a 
tethered signaling peptide is required for its own activation (Cottrell et al., 2002; 
Trejo, 2003). Using primary OLs from PAR1 knockout mice, it has been shown 
that a KLK6-induced reduction in OL branching can be partially rescued (Burda 
et al., 2013). Further, administration of PAR1 agonists alone can block nerve 
signal conduction in the peripheral nervous system (Shavit et al., 2008). Thus, 
exacerbation of KLK6 activity may both directly impact OL and myelination in the 
CNS by targeting key proteins such as MBP, and also through indirect 
mechanisms such as activation of protease-activated receptor signaling. 
 The characterization of KLK6 expression has been studied on mature OLs 
and immature OPCs separately, but not dynamically throughout the process of 
maturation. Chapter two of this work focuses on elucidating the role of KLK6 in 
OL maturation. Levels of KLK6 expression are characterized throughout 
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maturation in rodent primary OPCs derived from neurospheres in response to 
growth factors and previously described agents of maturation. The 
consequences of KLK6 pathway activation and inhibition on maturation of OLs 
are then investigated using these same neurosphere-derived cells. 
 
b) Methods 
i. Neurosphere-derived OPCs 
 Neurospheres were isolated and passaged using methodology generally 
as previously described (Pedraza et al., 2014). Briefly, embryonic day 15 mouse 
cortex (C57BL6 #664, Jackson Laboratories) was harvested from timed-pregnant 
animals. All procedures performed on these animals were in accordance with 
regulations and established guidelines and were reviewed and approved by the 
Institutional Animal Care and Use Committee. Neurospheres were cultivated in 
DMEM/F12 (Gibco 11330032) with Penicillin-Streptomycin (Gibco 15140122), 
B27 without vitamin A (Gibco 12587010), and 10 ng/mL EGF (Peprotech AF-100-
15). To passage, the mouse NeuroCult Chemical Dissociation Kit (StemCell 
Technologies 5707) was utilized. To cultivate OPCs after passaging, 10 ng/mL 
bFGF (Peprotech AF-100-18b) and 10 ng/mL PDGF (Peprotech AF-100-13A) 
were added to media base and cells were grown on poly-d-lysine-coated 6-well 
or 96-well plates (N=3 wells per treatment group). To mature OPCs to OLs, the 
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addition of either 3 µM T3 (3,3',5-triiodo-L-thyronine; Sigma-Aldrich T2752) or 
3 µM benztropine [Benztropine mesylate; Sigma-Aldrich SML0847; (Deshmukh 
et al., 2013)] was added to media at plating. 
 
ii. qRT-PCR 
 To isolate mRNA from cells, RNA isolation kit (Qiagen 74104) was utilized 
after QIAzol (Qiagen 79306)-chloroform (EMD Millipore CX10577) extraction 
from 6-well plated cell substrate. A genomic DNA degradation step was included 
(Qiagen 79254). Samples were assessed for concentration and purity using a 
Nanodrop instrument and reverse-transcribed to cDNA using SuperScript VILO 
mastermix (Invitrogen 11755-050). TaqMan assay probes (Life Technologies, 
see Table 1) were run with TaqMan Gene Expression Master Mix (Life 
Technologies 4370074) using CFX (Bio-Rad) for qRT-PCR. The 2-[Delta][Delta] 
CT method was utilized to quantify and compare relative gene expression across 
treatment groups (Livak and Schmittgen, 2001). Statistical analysis (two-way 
ANOVA or one-way ANOVAs with Dunnett or Sidak post-hoc comparison) was 
conducted using GraphPad Prism 7. 
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iii. Immunocytochemistry 
 To study distinct cell populations across stages of oligodendrocyte 
maturation, cell samples for immunocytochemistry were fixed with 4% 
paraformaldehyde and washed with phosphate-buffered saline. Before staining, 
samples were generally permeated with 0.5% tritonX-100 and blocked with 10% 
animal normal serum correlating to the host species of intended secondary 
antibodies. Primary antibodies (see Table 2) were incubated at 4 degrees 
Celsius overnight. The next day, secondary antibodies (AlexaFluor, Life 
Technologies or Jackson ImmunoResearch) were added, and DAPI (Life 
Technologies) was used as a counterstain. Plates were imaged using an InCell 
5000 (GE) or Cell Discoverer 7 (Zeiss). The total number of MBP positive cells 
per well and total MBP process length was counted manually for each well or 
custom-generated algorithm developed using CellProfiler (Kamentsky et al., 
2011). The total number of NG2 positive cells per well was obtained using a 
custom-generated algorithm developed also using CellProfiler. 
 
iv. Test Materials for KLK6, PAR1 Modulation 
 To modulate kallikrein 6 the following enzyme and inhibitor were used: a) 
recombinant full-length human KLK6 protein made in HEK293 cells (Abcam 
ab155642); b) KLK6 inhibitor [MW 548.68, IC50 1.5 µM; table 1, item 5 shown in 
(Liang et al., 2012a)] synthesized from a previously published virtual screening 
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effort which identified small molecules with amidinothiophene P1 group 
structures capable of KLK6 inhibition (Liang et al., 2012a; Liang et al., 2012b; 
Liang and Bowen, 2016). This is the first known application of the KLK6 inhibitor 
in biological assays beyond initial demonstration of KLK6 enzyme inhibition. 
 To modulate protease activated 1 receptor the following activating peptide 
and small molecule inhibitor were used: a) PAR1-activating peptide, PAR1 AP, 
(Peptides International PAR-3665-PI), with the sequence H-Thr-Phe-Leu-Leu-
Arg-NH2; b) PAR1 selective inhibitor Q94 hydrochloride (Tocris 4755, IC50: ~10-
100 nM). Both PAR1 modulators have previously been used to study PAR1 
modulation (Asteriti et al., 2012; Burda et al., 2013), although the specific 
inhibitor has had limited use in assays similar to those employed in the current 
study. 
 
v. Fluorescence-based dynamic calcium imaging by FLIPR 
 To assess PAR1AP activity, cells for calcium-based imaging were 
cultivated as described above, and plated into poly-d-lysine coated 96-well 
microclear plates (Greiner Bio-One, 655946). Four days prior to imaging, cells 
were treated with 3 µM T3 (Sigma-Aldrich T2752). Calcium indicator dye kit Fluo-
4 NW (Molecular Devices F36206) was used according to manual specifications 
on the day of the experiment. Just before analysis, a FLIPR Tetra system 
(Molecular Devices) was used to apply 150 ng/µL PAR1AP (Peptides 
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International) or 300 nM KLK6 enzyme (Abcam) directly to the test wells in a pre-
warmed 37 degrees Celsius environment. Fluorescent readings were recorded 
every second for the first five minutes (300 seconds) following treatment 
application. After this time period, timing between fluorescent readings was 
increased to be captured every minute for the following 25 minutes. Data was 
captured using ScreenWorks 4.0.0.30 (Molecular Devices) then analyzed as 
average relative fluorescent units over the time duration specified. 
 
vi. Serine Protease Activity Assay 
 A systems fluorogenic peptide substrate, Boc-QAR-AMC (R&D Systems, 
ES014), was utilized in combination with SpectraMax M5e (Molecular Devices) to 
assess ability of KLK6 enzyme to cleave basic amino acid arginine-AMC bond 
which creates detectable fluorescence upon cleavage with excitation/emission at 
380/460 nm. A kinetic experiment collected readings every minute for 30 minutes 
using SoftMaxPro Software version 5.4 (Molecular Devices). 
 
vii. RNA Sequencing 
 RNA from cell experiment treatment groups was isolated using a RNeasy 
Plus Universal Mini Kit (Qiagen 73404) after QIAzol (Qiagen 79306)-chloroform 
(EMD Millipore CX10577) extraction. Concentration and purity of RNA were 
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accessed using a NanoDrop fluorospectrometer (ThermoFisher Scientific). 
Stranded cDNA libraries were prepared using a TruSeq HT kit (Illumina), and 
sequenced on a NextSeq 500 (Illumina) at a read depth of 10-20 million reads 
per sample. FASTQ (reads generated with quality scores for each read) files 
were aligned to mouse (mm10) genomes using spliced transcripts alignment to 
reference method (STAR), and differentially expressed genes were determined in 
R (R Core Team, https://www.R-project.org) using DeSeq2 (Love et al., 2014), 
and examining statistical significance of genes with a greater than two-fold 
change and p value of less than 0.05. Analysis of common pathways of altered 
genes was done using Ingenuity Pathway Analysis (QIAGEN, version 42012434, 
latest patch June 2017). Pathways were assessed compared to enrichment 
score [-log(p value], and thus p values at or lower than p < 0.050 translate to a 
enrichment score at or above 1.3. 
 
c) Results 
 The process of OPC to OL maturation was examined using embryonically-
derived mouse neural stem cells cultured as neurospheres and treated with 
growth factors, then T3, or muscarinic receptor antagonist benztropine (Figure 1, 
A-C). Immunocytochemical cells counts and relative gene expression 
assessment by qRT-PCR demonstrate that T3 and benztropine treatment 
promoted maturation of OPCs to OLs, as defined by an increase in the 
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expression of mature oligodendrocyte markers MBP or MOG (Figure 1, 
D,F,G,J,K). Compared to vehicle (DMSO) treatment, T3 or benztropine resulted 
in an increase in endogenous KLK6 gene expression, in addition to an increase 
in genes indicative of oligodendrocyte maturation like MBP and MOG (Figure 1, 
F-H, J-L). In contrast, gene expression of CSPG4 (NG2) present on 
oligodendrocyte precursors did not statistically significantly change with T3 or 
benztropine treatment (Figure 1 E, I). In samples that were collected every 24 
hours for a maximum of 5 days after plating with T3, peak KLK6 expression was 
similar to the time of peak MBP expression (day 3; Figure1 F, H). MOG was also 
highly expressed at this time compared to vehicle, but peaked at a later time 
point (day 4; Figure 1G). By two-way ANOVA analysis, a statistically significant 
interaction was seen with KLK6 expression and with MOG expression over 5 
days maturation with both time and T3 treatment (p < 0.001). The same analysis 
for MBP expression was statistically significant interaction with treatment 
(p < 0.0001), but only a trend with regard to time (p = 0.10), likely due to 
variability. By two-way ANOVA analysis, only a statistically significant difference 
with time was seen with CSPG4/NG2 over the course of maturation (p < 0.0001; 
Figure 1E). This latter effect likely reflects factors in culture such as continuation 
of exposure to growth factors and culture density. A separate experiment was 
done to statically examine just the timepoint of maturation between 3-4 days with 
T3 or benztropine treatment compared to DMSO (Figure 1, I-L). The same 
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patterns emerged: no change in CSPG4/NG2 between treatment at this timepoint 
(Figure 1I), indicating that treatment-dependent changes on OPCs are unlikely to 
be present. Benztropine and T3 both statistically significantly increased MBP 
expression by five-fold compared to vehicle (DMSO), indicating increases in a 
gene associated with mature oligodendrocytes (Figure 1J). Similar or greater 
effect size increases were seen with MOG and KLK6 expression with 
benztropine or T3 maturation of OPCs at this timepoint as well (Figure 1K-L). 
Taken together, these data suggest that KLK6 is more highly expressed at the 
same time when mature oligodendrocytes genes are expressed. 
 To examine the consequences of high KLK6 expression, exogenous 
enzymatically active KLK6 (Figure 2A) or PAR1AP (Figure 2B-C) was utilized to 
mimic upregulation of KLK6 in OPCs over the course of their maturation to OLs. 
The number of OLs, defined as MBP-positive cells per well, was decreased with 
either KLK6 or PAR1AP treatment (Figure 2D). The MBP-positive cell mean 
process length was also reduced with PAR1AP treatment, but this effect was not 
seen with KLK6 (Figure 2E).  Thus, the data suggest that KLK6 has a negative 
effect on mature oligodendrocytes. 
 To examine the role of KLK6 inhibition on OPC to OL maturation, a KLK6 
inhibitor was used.  First, it was determined that pre-incubation with a KLK6 
inhibitor could block KLK6 enzyme cleavage activity in a cell-free assay (Figure 
2F). As a control, pre-incubation of a PAR1 inhibitor did not block KLK6 activity in 
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the same assay. Next, the KLK6 inhibitor was applied to OPCs with or without 
the presence of T3. KLK6 inhibition increased the number of cells positive for 
mature oligodendrocyte marker MBP (Figure 2G, O, green) and OPC marker 
NG2 (Figure 2I, O, red). However, the largest effect size, a 50% increase, was 
seen in MBP positive cell count when comparing T3 to T3/KLK6i combination 
treatment (Figure 2 G, P, green). Compared to T3 treatment alone, T3/KLK6i 
treatment also increases the median MBP-positive cell process length in a 
statistically significant fashion (Figure 2H). Overall, these data suggest that 
KLK6 inhibition can promote an increase in oligodendrocytes, and potentially 
more so in the presence of other maturation factors. To understand the 
differences between the T3 and T3/KLK6i combination treatments, RNA from a 
similar experimental design was analyzed using RNAseq and Ingenuity Pathway 
Analysis. Table 3 demonstrates the top 5 canonical pathways elevated across 
treatment contrasts where T3/KLK6i has a larger enrichment score compared to 
T3 alone. All five of these pathways reflect changes in genes relevant to 
cholesterol biosynthesis. 
 To examine whether PAR1 inhibition could mediate similar effects as 
KLK6i inhibition, application a PAR1 inhibitor was applied to OPCs in a similar 
experiment. PAR1 inhibition did not increase gene expression of MBP or NG2 
relative to T3 alone treatment or when combined with T3 treatment (Figure 2J, L, 
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S-T). Additionally, PAR1 inhibition did not impact process length of MBP positive 
cells in culture (Figure 2K). 
 
d) Discussion 
 In chapter two of this work the endogenous levels of KLK6 are examined 
in response to maturation of primary murine neural stem cell-derived 
oligodendrocytes. Over the course of maturation of oligodendrocytes from neural 
stem celIs I found that peak KLK6 expression levels during maturation in vitro are 
associated with early myelinating oligodendrocytes that express MBP. 
Expression of KLK6 decreases in more mature oligodendrocytes as determined 
by MOG messenger RNA levels. Taken together, these data suggest that in an in 
vitro system of primary rodent oligodendrocyte maturation, KLK6 is most highly 
associated with myelinating oligodendrocytes instead of oligodendrocyte 
precursor cells or more mature oligodendrocytes. This dynamic examination of 
KLK6 expression throughout maturation of oligodendrocytes complements 
previously published static data which has demonstrated KLK6 expression in 
newly-differentiated to myelinating rodent primary oligodendrocytes obtained via 
RNA sequencing analysis by immunopanning technique and single-cell level 
isolation methods (Zhang et al., 2014; Zeisel et al., 2015).  
 The use of neural stem-cell derived primary rodent oligodendrocytes as a 
model allows for a more high-throughput investigation in of maturation than in 
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isolated primary cells because neural stem cells are a continuously regenerative 
source of starting material. This approach also allows for the exploration of 
oligodendrocyte dynamics in vitro while in a heterogeneous environment that 
includes other cells types such as oligodendrocyte precursor cells and 
astrocytes. Unlike the cellular environment in vivo, this paradigm does not 
include the contributions of neurons, an important component in oligodendrocyte 
maturation and myelination. Another caveat of this model of oligodendrocyte 
maturation is that the process of maturation is artificially induced. The neural 
stem cells are driven towards oligodendrocyte precursors with growth factors 
present endogenously during maturation, and matured to oligodendrocytes with 
exogenous differentiation factors (like thyroid hormone T3 and muscarinic 
antagonist benztropine). Immunopanning is an example of a technique in which 
cells can be isolated at their current state of maturation versus artificial induction, 
although this process results in fewer cells and involves manipulation that may 
damage cells. The similarities of the overall results of KLK6 expression inquiry 
using these different techniques suggests that the result is reproducible and the 
in vitro maturation model system comparably models in vivo maturation. Further, 
the high expression level of KLK6 has now been shown by in vivo maturation and 
two different exogenous maturation factors: T3 and muscarinic antagonist 
benztropine. It remains to be further explored whether different maturation 
environments or agents produce different levels of KLK6 or whether KLK6 is 
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driven by oligodendrocyte maturation state. The result of the timecourse 
experiments with T3 treatment suggests that KLK6 expression may be driven by 
oligodendrocyte maturation state. Although the data within this work could be 
interpreted as benztropine induces a higher level of KLK6 expression than T3, 
another explanation is that different concentrations of each agent result in 
maturation differences driven by potency or mechanism at the same time point 
analyzed. 
 The next question is what are the functional consequences of elevated 
KLK6 expression? It is known that KLK6 levels are increased in normal newly-
differentiating and mature oligodendrocytes (Zhang et al., 2014; Zeisel et al., 
2015; Zhang et al., 2016). In addition, KLK6 has been shown to be increased in 
multiple sclerosis patients compared to control (Scarisbrick et al., 2002; 
Scarisbrick et al., 2008; Hebb et al., 2010). However, multiple sclerosis patients 
generally have less myelination and less mature oligodendrocytes (Lucchinetti et 
al., 1999). Does KLK6 promote or refine maturation by oligodendrocytes or does 
it negatively regulate maturation? KLK6 knockout animals have been found to be 
largely normal (Murakami et al., 2013). However, early in development (P7) they 
showed a slight delay in maturation that was resolved by P14 (Murakami et al., 
2013). They also showed that after white matter injury, KLK6 knockout animals 
had less white matter damage as indicated by increased MBP expression 
(Murakami et al., 2013). These results suggest that the absence or abundance of 
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KLK6 may negatively regulate maturation of oligodendrocytes and myelination.  
MBP, a protein found on mature oligodendrocytes, has been shown to be a 
substrate of KLK6 (Blaber et al., 2002), which provides rationale for why an 
abundance of KLK6 could be result in a decrease of myelination, as in seen in 
MS patients. Exogenous KLK6 has also been shown to decrease branching in 
mature rodent oligodendrocytes, with no impact on oligodendrocyte number 
(Burda et al., 2013).  
 After validating the activity of a commercially available human full length 
recombinant KLK6 enzyme to cleave basic amino acids, I applied the enzyme to 
neural stem cell-derived OPCs in the presence of maturation factor T3. I found 
that the exogenous application of KLK6 decreased the number of MBP-positive 
oligodendrocytes over a 4 day maturation period. In contrast to previous 
literature, exogenous application of KLK6 did not decrease the amount of 
branching of MBP-positive cells during the same period. The results suggest that 
application of exogenous KLK6 negatively regulates oligodendrocyte maturation. 
However, a decrease in number of oligodendrocytes and decreased branching of 
oligodendrocytes could point to either a lack of oligodendrocyte maturation or an 
increase in cellular pathology and death. Burda et al. demonstrated that 
exogenous application of KLK6 to primary oligodendrocytes increased 
exogenously-introduced ATP excitotoxicity while also decreasing structural 
complexity of the cells and resulting in a decrease of oligodendrocytes (Burda et 
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al., 2013). I evaluated whether levels of lactate dehydrogenase (LDH) increased 
in cell media due to cell death after KLK6 application, and did not see a 
difference between treatment and control (data not shown). However, this result 
could be due to the dilution and heterogeneous nature of the maturation culture 
model. Current data from the combined studies suggests that although KLK6 can 
exacerbate cell death, it doesn’t directly promote it on its own. Thus, KLK6 is 
likely negatively impacting maturation of OPCs to oligodendrocytes.  
 Differences in phenotypes observed with exogenous KLK6 application 
between this work and the literature (such as changes in cell number vs. 
branching complexity) could be attributed to different assay parameters. For 
example, I examined MBP as an oligodendrocyte marker in neural stem cell-
derived OPC cultures while Burda et al. examined sulfatide (O4) in mixed glia 
derived OPC cultures. Distribution of staining is unlikely to be the same due to 
the nature of MBP as a protein and sulfatide as a sulfated form of lipid 
galactocerebroside (Coetzee et al., 1996). It is likely that using a lipid marker 
would result in more robust resolution of myelin structure and oligodendrocyte 
branching, especially as it is one of the earlier markers of oligodendrocyte 
maturation, is expressed before MBP, and can impact MBP function in packing 
myelin (Dyer et al., 1997). Thus, fewer cells may be staining with MBP versus 
O4, and the cells may represent different time points in maturation. Additionally, 
different treatment and analysis paradigms were utilized, with my paradigm being 
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slightly stronger in concentration and longer in duration. This might result in 
visualization of a more pronounced (cell loss) phenotype compared to the 
decreased branching phenotype observed with a shorter incubation by Burda et 
al. Further, the KLK6 enzymes across the studies were from different species: 
human versus mouse. Alignment of protein for human (NP_002765) and mouse 
(NP_001158170) KLK6 demonstrates only 68% homology across species via 
NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi), which could be associated 
with functional consequences across species. 
 In order to determine if the negative effect of KLK6 on oligodendrocyte 
maturation could be blocked, a small molecule KLK6 inhibitor was identified in 
the literature and synthesized (Liang et al., 2012a). In a cell-free assay, the KLK6 
inhibitor was confirmed to block KLK6 enzyme activity from cleaving basic amino 
acids. Next, the KLK6 inhibitor was applied to neural stem cell-derived OPCs at 
twice the concentration of the IC50 (1.5 µM; 3 µM) with and without exogenous 
maturation agent T3. I found that the KLK6 inhibitor increased the number of 
MBP-positive oligodendrocytes in culture and the number of NG2-positive OPCs 
in culture. There was a trend for an increase in MBP-positive cell branch length 
with KLK6 inhibitor treatment, but it did not achieve statistical significance at 
p = 0.055. When combined with T3, the KLK6 inhibitor increased the number of 
MBP-positive oligodendrocytes compared to either treatment alone. Additionally, 
the combination treatment increased the total branching length of MBP-positive 
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cell processes per cell compared to T3 treatment alone, indicating the cells to 
have greater complexity. The number of NG2-positive OPCs did not differ 
between the T3 alone and combined treatment conditions, indicating that KLK6 
inhibitor treatment could not maximize maturation at this stage compared to T3 
alone. This is the first demonstration of a KLK6 small molecule inhibitor to 
enhance maturation of oligodendrocytes in vitro. Previously, KLK6-neutralizing 
antibodies have been shown to enhance myelination in the spinal cord during 
early stages of a viral model of demyelination (Scarisbrick et al., 2012b). It is 
expected that an increase in branching and number of oligodendrocytes would 
translate to an increase in myelination, but this remains to be evaluated in in vitro 
model systems such as dorsal root ganglion neuron/OPC co-cultures or in vivo. 
 To determine the mechanism by which the combination of KLK6 inhibitor 
and T3 treatment synergistically increased MBP expression compared to either 
treatment alone, RNA sequencing was conducted on a separate cohort of cells 
run in a similar way as the experiment where analysis was done at the protein 
level. Then, Ingenuity Pathway Analysis was used to examine expression 
changes in common canonical biological pathways of genes across treatment 
contrasts. The five top pathways with highest enrichment score for the 
combination treatment are all involved in cholesterol synthesis. Additionally, the 
enrichment scores across comparisons reflect the same pattern seen with the 
protein cohort: lowest enrichment with KLK6 inhibitor alone, higher enrichment 
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with T3 alone, and highest enrichment with the combination of the two. Given this 
finding, future research might include lipidomics analysis to see whether 
differential lipid structures are being produced in response to combination 
treatment. 
 Cholesterol synthesis in the brain, unlike elsewhere in the body, is derived 
largely from astrocytes instead of from diet due to the blood-brain barrier (Kiray 
et al., 2016). Thus, by extension it is hypothesized that KLK6 inhibition enhances 
maturation of oligodendrocytes by promoting astrocyte synthesis of cholesterol. 
Although the neural stem cell model system being used favors development of 
OPCs and oligodendrocytes, astrocytes and oligodendrocytes are derived from a 
shared developmental precursor (Li et al., 2016), and GFAP-positive astrocytes 
are present within the cultures (data not shown).  
 
 It has previously been reported that KLK6 signaling is at least partially 
mediated through the protease-activated receptor 1 (PAR1), which then activates 
the ERK pathway and ultimately results in modulation of calcium ions (Burda et 
al., 2013). I validated activity of a PAR1-activating peptide (PAR1AP) to induce 
calcium release in neural stem-cell derived OPCs/oligodendrocytes using a 
calcium-sensitive dye and FLIPR. Under the parameters tested, PAR1AP 
induced a calcium response with the first five minutes, but a KLK6 enzyme, 
whose ability to cleave proteins also validated, did not elicit a calcium response 
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within 30 minutes. This suggests that a mechanism link between KLK6 and 
PAR1 that elicits calcium modulation is not direct. However, it could also be that 
the concentration KLK6 enzyme used was not sufficient or comparable to the 
amount of PAR1AP used, as PAR1AP is a direct agonist of the pathway. When I 
applied the PAR1AP to neural stem cell-derived OPCs in the presence of T3, I 
found the number of MBP-positive cells and the length of MBP-positive branching 
per cell to be decreased. This corroborates the literature finding that PAR1AP 
reduces branching of oligodendrocytes as visualized using sulfatide (O4) (Burda 
et al., 2013). It is also a similar finding to what was achieved with the KLK6 
enzyme in this work: both reduced oligodendrocyte maturation in neural stem 
cell-derived OPCs despite the presence of T3. If the PAR1AP is more direct 
stimulation of a downstream pathway, this could also explain a more pronounced 
phenotype in that decreased MBP branching was a result with PAR1AP but not 
with KLK6 treatment.  
 To evaluate if PAR1 inhibition can enhance oligodendrocyte maturation, a 
commercially available small molecule PAR1 inhibitor was obtained. It was 
evaluated against KLK6 enzyme in a cell-free activity assay to determine if the 
PAR1 inhibitor could block KLK6 cleavage and it was found that it could not. The 
PAR1 inhibitor (IC50 10-100 nm) was applied at two concentrations: 100 nm and 
500 nm. Neither concentration alone or in combination with maturation agent T3 
elicited a change in number of MBP-positive oligodendrocytes, NG2-positive 
40 
 
 
OPCs, or in MBP process length compared to vehicle treatment. Thus, while 
PAR1AP induced deficits in oligodendrocyte maturation in vitro, inhibition with 
this PAR1 inhibitor did not enhance maturation. Because this compound has 
been shown to modulate PAR1-specific calcium signaling (Asteriti et al., 2012), 
and because it was dosed well above the IC50, alternate explanations include that 
the pathway cannot be modulated in the reverse direction, or that the model 
system of oligodendrocyte maturation that is being used leaves out an important 
component required for inhibitor modulation and perhaps it would be efficacious 
in a more holistic environment (such as in vivo). However, a different PAR1 
inhibitor (SCH79797) has been recently found to promote maturation of OPCs in 
vitro (Yoon et al., 2015). The two compounds are structurally distinct, although 
they have similar IC50s, and are both reported to be PAR1-selective compared to 
other PAR receptors (2-4). The reason why this particular PAR1 inhibitor was 
chosen for this work was ultimately so we could test the compound in in vivo 
myelination assays, as its chemical structure suggested it was the most likely to 
be brain penetrant compared to other commercially available PAR1 inhibitors (J. 
Tuttle, B. O’Neill, personal communication). To better compare and contrast 
properties of these PAR1 inhibitors, it would be ideal to test them at the same 
time in the OPC maturation assay, and to further profile these compounds for 
specific binding and selectivity differences. Because use of PAR1 knockout 
mouse oligodendrocytes reduce pathology induced by KLK6 enzyme in culture 
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compared to wildtype (Burda et al., 2013), further development towards a single 
small molecule that is both brain-penetrant and selectively inhibits PAR1 may be 
a useful secondary approach to inhibiting KLK6. 
 In summary, the work within this chapter demonstrates KLK6 to be a 
negative regulator of oligodendrocyte maturation in vitro, and identifies a KLK6 
inhibitor that promotes oligodendrocyte maturation. The effects of the KLK6 
inhibitor are synergistic in the presence of another maturation agent (T3) than 
either agent alone, and this is likely due to enhancement of astrocyte cholesterol 
synthesis pathway. Next steps include testing whether KLK6 inhibition can also 
promote myelination in addition to oligodendrocyte maturation. 
 Additionally, KLK6 downstream impact on oligodendrocyte pathway has 
been previously shown to be partially mediated through PAR1. A PAR1AP 
demonstrated that exogenous agonism of PAR1 resulted in decreased 
oligodendrocyte maturation. A PAR1 inhibitor was unsuccessful at enhancing 
oligodendrocyte maturation in the in vitro model. Although it is expected that the 
results of test compounds in the oligodendrocyte maturation in vitro assay will 
inform likelihood of success in an in vivo myelination model, this is a prediction 
until it is tested. 
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Table 1. qRT-PCR TaqMan Primer Assays 
 
 
 
Table 2. Chapter 2 Antibody Information 
 
 
  
Full Name Gene Name Catalog Code Dye 
Chondroitin sulfate 
proteoglycan 4 (Neural/Glial 
proteoglycan antigen 2) 
CSPG4 Mm00507257_m1 
 
FAM 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH 4352339E VIC 
Kallikrein 6 KLK6 Mm00478322_m1 FAM 
Myelin basic protein MBP Mm01266402_m1 FAM 
Myelin oligodendrocyte 
glycoprotein 
MOG Mm00447824_m1 
 
FAM 
Plate-derived growth factor 
receptor alpha 
PDGFRa Mm00440701_m1 FAM 
Full Name Short 
Name 
Vendor Catalog 
Code 
Host  
Species 
Tissue Tested 
Species 
Myelin Basic 
Protein 
MBP AbD Serotec MCA409S Rat Mouse, 
Human 
Neural/Glial 
proteoglycan 
antigen 2 
NG2 Millipore AB5320 Rabbit Mouse, 
Human 
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Canonical Pathway KLK6i vs DMSO T3 vs DMSO KLK6i T3 vs T3 KLK6i T3 vs KLK6i 
Superpathway of 
Cholesterol 
Biosynthesis 
0.5010 5.2434 15.5056 1.0993 
Cholesterol 
Biosynthesis I 
0.7923 4.5960 11.9348 1.0527 
Cholesterol 
Biosynthesis II 
0.7923 4.5960 11.93487 1.0527 
Cholesterol 
Biosynthesis III 
0.7923 4.5960 11.9348 1.0527 
Zymosterol 
Biosynthesis 
1.108 3.2463 5.3883 1.0782 
Table 3. Top 5 canonical pathways of OPC altered gene expression with KLK6/T3 treatment versus T3 alone 
Table 3 values demonstrate enrichment scores within canonical pathways from 
Ingenuity Pathway Analysis. Enrichment score is representative of a negative log 
of the associated p value based on RNAseq data. Thus, a p value of p = 0.050 is 
equal to a score of 1.3, and as the p value becomes smaller in magnitude than p 
= 0.050, the enrichment score becomes larger in magnitude than 1.3. The top 5 
canonical pathways are shown that demonstrate RNA changes with KLK6/T3 
treatment compared to the treatments alone on stem cell-derived OPCs in 
culture. 
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Figure 1. Peak of KLK6 Expression in Oligodendrocyte Maturation is 
Similar to MBP Peak of Expression. 
 
To examine maturation of oligodendrocytes in vitro, embryonically-derived mouse 
neural stem cells were passaged as neurospheres (A; brightfield, 200 µm scale 
bar). Growth factors were used to commit cell lineage to oligodendrocyte 
precursor cells (B; red, NG2, 50 µm scale bar), whereupon they were plated and 
used for maturation experiments. Thyroid hormone T3 and muscarinic antagonist 
benztropine have been previously shown in the literature to mature 
oligodendrocyte precursor cells to oligodendrocytes. C: An example of a mature 
oligodendrocyte (green, MBP, 50 µm scale bar) in culture by T3 or benztropine. 
D: Quantification of number of MBP-positive cell T3-mediated maturation versus 
vehicle control, stained by immunocytochemical methods (n = 3-12 ninety-six 
wells per treatment).  E-L: OPCs were treated with T3, benztropine, or vehicle 
and incubated for up to five days with samples taken for mRNA expression 
analysis by qRT-PCR (n = 3 six-wells per timepoint/treatment). All expression 
data is normalized by GAPDH control.  E-H: A five-day timecourse illustrates 
KLK6 mRNA expression to be increased in T3-treated OPCs at day 3 compared 
to vehicle treatment. This is notably similar to oligodendrocyte data shown with 
MBP expression. Peak MOG expression, expressed later than MBP in 
maturation, is right-shifted compared to both KLK6 and MBP expression.  NG2 
(CSPG4) expression is unaffected by T3 maturation of OPCs but increases over 
45 
 
 
time, likely due to factors such as cell density and continued presence of growth 
factors.  I-L: Static timepoint four days after benztropine or T3 administration to 
OPCs shows statistically significant increases in KLK6, MBP, and MOG (but not 
NG2/CSPG4) expression compared to vehicle treatment. Statistical analyses 
were done using two-way ANOVA or one-way ANOVA with Dunnett post-hoc 
comparison. All graphs within the figure represent the data as mean plus or 
minus the standard error of the mean. 
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Figure 2. Exogenous Activation of KLK6 Pathway Decreases OL-Related 
Markers; Inhibition of KLK6 Increases OL-Related Markers 
 
A: Recombinant full-length human KLK6 protein is determined to be 
enzymatically active using Boc-QAR-AMC serine protease cleavage assay. B-C: 
T3 (3 µM) was applied to OPCs for 3-4 days whereupon Fluo-4 calcium dye was 
added and then fluorescence was monitored in response to enzymatically-active 
KLK6 (300 nM) or PAR1 Activating-Peptide (PAR1AP; 150 ng/µL) using a FLIPR 
Tetra (every second for the first 5 minutes, every minute for the following 25 
minutes). PAR1AP but not KLK6 enzyme induces a calcium response in OPCs / 
OLs. D-E: Enzymatically-active KLK6 (300 nM) or PAR1AP (150 ng/µL) was 
applied to OPCs and incubated in the presence of T3 for 3-4 days, whereupon 
samples were collected for immunocytochemical analysis. D: The number of 
MBP+ cells/well is decreased with either PAR1AP or active KLK6 treatment. E: 
The mean length of processes on MBP+ cells was reduced with PAR1AP 
treatment, but not KLK6 treatment. F: Pre-incubation of an inhibitor of KLK6 
blocks activity of KLK6 in a cell-free assay. As expected, pre-incubation of a 
PAR1 inhibitor does not block KLK6 activity. N = 2 ninety-six wells per treatment 
condition. Statistical analyses were done using a one-way ANOVA with a 
Dunnett post-hoc comparison. G-T: OPCs were plated and incubated with 
vehicle (DMSO), T3 (3 µM), KLK6 inhibitor (3 µM), PAR1 inhibitor (100 or 500 
nM), or T3/test compound combination for 3-4 days & then stained for MBP & 
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NG2. KLK6 inhibition increased the number of MBP+ (green) and NG2+ (red) 
cells. However, a larger increase was seen in combination with T3 treatment 
(MBP+ cells & length of MBP+ processes).  PAR1 inhibition did not have an 
impact on number of NG2+ cells or number of cells and length of processes in 
MBP+ cells. N = 6 ninety-six wells per treatment condition. Statistical analyses 
were done using a one-way ANOVA with a Sidak post-hoc comparison. Scale 
bar = 100 µm. All graphs within the figure represent the data as mean plus or 
minus the standard error of the mean. 
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CHAPTER THREE 
Kallikrein 6 in Oligodendrocyte Myelination 
a) Introduction 
i. Animal Models of Oligodendrocyte Demyelination & Remyelination 
 Several in vivo assays model aspects of demyelination in rodents and are 
used with the hope of understanding and reversing pathology in a mammalian 
species similar enough to apply findings to human patients, such as those with 
chronically demyelinating disorder multiple sclerosis (MS). Neuroinflammation is 
a significant contributor to MS pathology (Dendrou et al., 2015). Models such as 
experimental autoimmune encephalomyelitis (EAE) and Theiler’s murine 
encephalomyelitis virus (TMEV) are used to study remyelination in the context 
where demyelination is a direct consequence of induced inflammation in the CNS 
(Ransohoff, 2012).  
 The EAE model is one of the most extensively used to study 
demyelination and potential therapies for MS. Similar to MS, the EAE model 
induces demyelination of white matter tracts through inflammation-driven 
processes that involve T lymphocytes. There are multiple paradigms in which the 
EAE model can be established; paradigms to create the EAE model generally 
include the peripheral injection of inflammation-inducing agents (e.g. 
complete/incomplete Freud’s adjuvant, mycobacterium tuberculosis, pertussis 
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toxin) in conjunction with a myelin protein peptide (e.g. MOG35-55, MBP84-104, 
PLP178-191) (McCarthy et al., 2012). In this way, an immune response is directed 
at a component of myelin. Demyelination and inflammation depends on the major 
histocompatibility complex type of the mouse strain and antigen provided. For 
example, in C57BL6 mice MOG35-55 primarily demyelinates white matter of the 
spinal cord and not the brain; in SJL/J mice PLP139-151 leads to demyelination in 
both the brain and spinal cord (Constantinescu et al., 2011). In addition to 
demyelination and T cell infiltration visible by immunohistochemistry, the EAE 
model induces behaviorally observed motor deficits. Depending on the 
parameters of induction, paralysis can take two to four weeks to plateau; 
paralysis is scored by grades 0-5 where grade 0 is no paralysis, grade 2 is both 
hind limb and tail weakness, grade 4 is full hind limb paralysis, and grade 5 is 
complete limb paralysis (McCarthy et al., 2012; Rangachari and Kuchroo, 2013). 
 The TMEV model of progressive demyelination (also termed TMEV-
induced demyelinating disease) is another animal model which induces myelin 
loss via an inflammatory process. TMEV is a picornavirus that is normally found 
in without pathogenic symptoms in the mouse gut (DePaula-Silva et al., 2017). 
The TMEV model is very dependent on mouse strain used: introduction of the 
virus in SJL/J mice evokes MS-like symptoms while C57BL6/J mice instead 
experience seizures hypothesized to be due to stronger innate immune system 
and different major histocompatibility complex subtype (Denic et al., 2011; 
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DePaula-Silva et al., 2017). It is injected into the brain directly (McCarthy et al., 
2012). Acutely after injection TMEV infects mainly neurons, but about a month 
later the virus is found in oligodendrocytes, microglia, and astrocytes (DePaula-
Silva et al., 2017). It is during this latter phase that demyelination begins in the 
spinal cord and paralytic motor deficits similar to those described above for the 
EAE model develop, although generally at a slower pace, with full hind limb 
paralysis expected around 6 months after injection (Denic et al., 2011; McCarthy 
et al., 2012). Similar to progressive forms of MS, the demyelination is progressive 
in nature and leads to neuronal death (Denic et al., 2011). The TMEV model itself 
is interesting because it creates a model in which viral load could result in MS-
like symptoms. Of note, while there is not a causative link of viral induction to 
MS, the Epstein-Barr virus (a double-stranded DNA herpesvirus) has been 
associated with MS or MS-like development in human and rodent (Pender and 
Burrows, 2014; Lomakin et al., 2017). The mechanism of TMEV model of 
demyelination is suggested to induce demyelination by regulatory T cell epitope 
spreading (McMahon et al., 2005; Richards et al., 2011). 
 
 To study remyelination without the complexity of triggering inflammation to 
attack myelin, as EAE and TMEV models described above enact, toxin-driven 
models such as lysophosphatidylcholine or cuprizone are used. Currently FDA-
approved therapeutics for MS target only neuroinflammatory aspects of the 
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disease (Ransohoff et al., 2015; Stahnke and Holt, 2017). A combination therapy 
that uses both an anti-inflammatory and a remyelination agent may be important 
to effectively treat MS as inflammation is a substantial pathology-inducing agent 
but also remyelination propensity decreases with age and promoting myelin 
repair can further protect axonal degeneration (Franklin and Ffrench-Constant, 
2017). While toxin-based models lack an immune-central component to the 
initiation of disease which could be interpreted as less appropriate for modeling 
MS in animals, they allow for dissection of remyelination aside from inflammatory 
injury. 
 Lysophosphatidylcholine (LPC; also known as lysolecithin) models of 
demyelination are derived from phospholipase A2 digestion of 
phosphatidylcholines, a lipid component of myelin (Pavelko et al., 1998). LPC 
recruits macrophages, microglia, T cells, and monocytes to digest myelin and 
myelin debris (Ousman and David, 2000; Ghasemlou et al., 2007). LPC creates 
focal lesions when injected into white matter- often directed into funiculi of spinal 
cord (Keough et al., 2015). Myelin debris from these processes is usually cleared 
by 7 days post-injection depending on parameters of model (Jeffery and 
Blakemore, 1995). LPC will deteriorate white matter regardless of CNS location, 
age, or gender of subject. Although it is delivered locally in vivo, as opposed to 
systemically, one to two microliters of a 1% solution in saline can affect an area 
as wide as 3-8 mm (Blakemore and Franklin, 2008; Keough et al., 2015). LPC 
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can also demyelinate ex vivo in organotypic CNS slice culture systems (Meffre et 
al., 2015). Remyelination of axons in this model is spontaneous; in an 
aforementioned sized demyelinated area it takes a little over 20 days to 
completely remyelinate all axons and involves astrocyte recruitment to the area 
(Jeffery and Blakemore, 1995). 
 The cuprizone model of demyelination uses bis-cyclohexanone-
oxaldihyrazone (also known as cuprizone), administered systemically, generally 
by incorporation into animal chow. Cuprizone is a chemical compound that binds 
or chelates copper (Benetti et al., 2010). At low doses it is exclusively toxic to 
mature oligodendrocytes (Matsushima and Morell, 2001). However, cuprizone 
does not demyelinate all CNS white matter to the same extent. This model is 
preferentially used to study the brain, due to lack of spinal cord demyelination 
with treatment (Herder et al., 2011). The corpus callosum is the white matter 
region in the brain most studied in this model. White matter pathology has also 
been noted in the hippocampal commissure (fornix and fimbria), as well as the 
cerebellar peduncles (Blakemore and Franklin, 2008). Smaller effects have been 
noted in gray matter regions such as the cerebral cortex (Petiet et al., 2016).  
 The exact mechanism by which cuprizone is toxic to mature OLs is 
unknown. However, it is hypothesized to be due to the disproportionately high 
cellular respiration levels of mature OLs (heavy metals are necessary cofactors 
in this process) compared to other cell types (Thorburne and Juurlink, 1996; 
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Matsushima and Morell, 2001; Gudi et al., 2014). Evidence for this postulate 
includes that cuprizone treatment has been shown to inhibit the mitochondrial 
enzymes carbonic monoamine oxidase and cytochrome c oxidase, as well as to 
enlarge mitochondria in the brain and liver of rodents (Gudi et al., 2014). 
 Differences in demyelination in this model can be caused by mouse strain, 
age, and gender, in addition to concentration and duration of dosing paradigm 
(Blakemore and Franklin, 2008; Kipp et al., 2009; Taylor et al., 2009; Skripuletz 
et al., 2011). In the corpus callosum these parameters can also exacerbate a 
rostrocaudal axis gradient in demyelination (Blakemore and Franklin, 2008; 
Steelman et al., 2012; Tagge et al., 2016). The toxic effects of cuprizone are 
demonstrated earliest (around one week of administration of chow) using gene 
expression assays that target markers of mature OLs (e.g. MBP, MOG). At a 
dose of 0.2% cuprizone, it takes about four to six weeks to see extensive 
demyelination by histologic methods (Matsushima and Morell, 2001). If cuprizone 
is removed at this point, it will take approximately four to five weeks to fully 
spontaneously remyelinate the demyelinated areas (Matsushima and Morell, 
2001; Deshmukh et al., 2013). The presence of microgliosis and astrogliosis in 
areas targeted by demyelination has been shown to likely be due to myelin 
debris clearance pathways (Clarner et al., 2012; Skripuletz et al., 2013). After 9-
12 weeks of cuprizone administration at the same dose, the model transitions to 
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a more severe chronic version where neurons become secondarily damaged in 
addition to myelin damage.  
  Unlike the EAE and TMEV demyelination models, the acute cuprizone 
model does not exhibit gross motor deficits like paralysis. Animals treated with 
0.2% cuprizone for acute length of time (~6 weeks) do not have overt changes in 
behavior (Skripuletz et al., 2011). A few laboratories have demonstrated changes 
in more complex behavioral assays (e.g. slower wheel-running compared to 
control mice when wheel has fewer rungs) with cuprizone treatment, but these 
findings have not yet been replicated across other groups (Hibbits et al., 2009). 
Animals treated with 0.2% cuprizone for chronic amounts of time exhibit seizures 
(Skripuletz et al., 2011; Lapato et al., 2017). The change in behavior after chronic 
treatment is suggested to be due to axonal loss. 
 
ii. Known Therapeutic Agents That Impact Remyelination in In Vivo MS Models 
 Several therapeutic mechanisms have been tested for remyelination 
propensity in remyelination animal model paradigms after cuprizone and LPC 
demyelination. Below, a few recent studies are highlighted where therapeutic 
agents (compounds or biologics) have been tested in these models. 
 Deshmukh et al. dosed the muscarinic 1/3 receptor antagonist benztropine 
at 10 mg/kg by intraperitoneal administration for up to 5 weeks following 7 weeks 
of 0.2% cuprizone demyelination in C57BL6/J mice (Deshmukh et al., 2013). Two 
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weeks after cuprizone withdrawal and administration of compound, they saw 
approximately a 10% increase in luxol fast blue stain (a histological stain for 
basic phospholipids in myelin) in the corpus callosum of the benztropine group 
compared to the spontaneous remyelination in the corpus callosum vehicle group 
(Deshmukh et al., 2013). Additionally, they tested benztropine (2.5mg/kg) as a 
combination treatment along with an anti-inflammatory approved for MS 
[fingolimod or interferon-beta (Ransohoff et al., 2015)], and found that the clinical 
severity score in EAE (PLP139-151, CFA & pertussis toxin) model was reduced with 
both combination treatments compared to either anti-inflammatory or pro-
remyelination treatment alone (Deshmukh et al., 2013). Benztropine is currently 
approved for Parkinson’s disease; and there is the potential for it to be dosed at 
concentrations that could provoke known adverse effects like tachycardia, 
anxiety, and depression (Hai et al., 2008; Deshmukh et al., 2013). Thus, despite 
its success in animal models of remyelination and inflammation-induced 
demyelination, benztropine itself is unlikely to be approved for MS. Another 
muscarinic receptor antagonist with a better safety profile would be more ideal. 
  Clemastine, a histamine 1 receptor antagonist marketed for allergies and 
that has high binding affinity for muscarinic receptors (Kubo et al., 1987), has 
been assessed for remyelination potential using the LPC model of remyelination. 
Mei et al. injected lysolecithin into white matter of the dorsal funiculus and 
ventrolateral spinal cord (between thoracic vertebrae T12/13) in 8 week old 
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C57BL6/J mice, dosing clemastine 10 mg/kg/day starting before demyelination 
(Mei et al., 2014). At 14 days post-lesion they found a 20% difference in 
myelinated axons compared to control; and a decrease in g-ratio (axon diameter 
/ axon diameter + myelin sheath; all assessed using electron microscopy) 
indicating clemastine increased myelination with treatment (Mei et al., 2014). In a 
separate experiment, the Chan laboratory also isolated OPCs from muscarinic or 
histamine receptor knockout mice, treated with clemastine & benztropine and 
saw the expected increase in mature OLs in every condition except the M1 
receptor knockout, indicating that M1 mediates the effect for both compounds 
(Mei et al., 2016). 
 The Chan laboratory also recently completed a small (n = 50) proof-of-
concept clinical trial with clemastine where RRMS patients with chronic 
demyelinating optic neuropathy received 5.36 mg clemestine twice per day 
during the test portion of a double-blind, randomized, cross-over trial (Green et 
al., 2017). Around 20% of the subjects demonstrated a 6 millisecond decrease in 
latency with visual-evoked potential conduction, which serves as an indirect 
measure of increased optic tract myelination (Green et al., 2017). No effect was 
seen with treatment by MRI, which the authors attribute to variability.   
 Fingolimod, a RRMS FDA-approved anti-inflammatory that prevents T cell 
infiltration [and efficacious treatment in EAE models (Webb et al., 2004)] by 
targeting sphingosine-1-phosphate, has been tested in both lysolecithin and 
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cuprizone models of remyelination. Hu et al injected sprague dawley rats with 
1.5 µL of 1% LPC into the dorsal white matter of the spinal cord and treated 3 
days later with 2 µL of 2 mg/mL fingolimod locally, then collected on day 10, and 
then stained with LFB for myelin (Hu et al., 2011). Fingolimod increased the 
amount of demyelination area (lack of LFB stain) compared to LPC vehicle alone 
(Hu et al., 2011). For the cuprizone demyelination study, Hu et al. treated 
C57BL6 mice with 0.3% cuprizone incorporated into chow for 4 weeks in 
combination with 10 mg/kg rapamycin [5 days/week, IP; to maximize 
demyelination (Sachs et al., 2014)] whereupon the cuprizone chow was removed 
and animals received 1mg/kg fingolimod for 2 weeks (Hu et al., 2011). No effect 
on remyelination was seen with fingolimod treatment compared to control in the 
corpus callosum using immunohistochemistry for MBP or by electron microscopy 
(Hu et al., 2011). Thus, fingolimod did not show efficacy in either the LPC or 
cuprizone model of remyelination, which indicates it may only improve 
remyelination caused by an inflammatory mechanism.  
 Another study from a different laboratory demonstrated that fingolimod is 
protective of mature oligodendrocytes in the cuprizone model of demyelination if 
it is dosed within 3 days but not at 10 days into demyelination (Kim et al., 2017). 
Thus, to the extent that oligodendrocyte damage in the cuprizone model is similar 
to MS oligodendrocyte damage, there is the potential fingolimod could protect 
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against new oligodendrocyte damage in MS. However, it will not enable repair or 
remyelination of axons. 
 LINGO-1(leucine rich repeat and Ig domain containing Nogo receptor 
interacting protein1) inhibits OL maturation which prevents myelination (Mi et al., 
2005). No anti-inflammatory effects of LINGO-1 antagonism are anticipated in 
rodent or humans (Ranger et al., 2018). LINGO-1 antagonists to inhibit 
endogenous OL maturation inhibition have been tested in the remyelination 
models lysolechithin and cuprizone. Mi et al. injected sprague dawley rats with 
1.5 µg of LINGO-1 antagonist 3 days post-injection of 250 g LPC in the spinal 
cord (Mi et al., 2009). A twenty-fold reduction in lesion (lack of LFB stain) 
occurred with LINGO-1 antagonist compared to control in the LPC model; by EM 
there were ~50% more myelinated axons with treatment (Mi et al., 2009). For 
assessment in the cuprizone model, LINGO-1 antagonist was stereotaxically 
injected into the corpus callosum at 2.5 and 3 weeks during cuprizone 
demyelination (% dosage not provided); animals were euthanized 4 and 6 weeks 
after treatment while still on cuprizone (Mi et al., 2009). LINGO-1 antagonist 
treated animals had a 4-fold increase in myelinated axons by EM in the corpus 
callosum; qualitative immunohistochemistry staining for MBP demonstrated no 
stain in the cuprizone vehicle and moderate stain in the treated (Mi et al., 2009). 
Thus, both LPC and cuprizone remyelination assays showed increased 
remyelination with LINGO-1 antagonist. However, the cuprizone assay is 
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somewhat confounded due to the fact that cuprizone was never removed from 
the model to test remyelination in the absence of demyelination.  
 A LINGO-1 antagonist (opicinumab, Biogen) has proceeded to a three 
phase 2 trials in demyelinating disease conditions so far. A 24-week trial in 82 
newly-diagnosed optic neuritis patients did not reach its primary endpoint, 
reduction in conduction latency measured by visual-evoked potential (Cadavid et 
al., 2017). However, patients that adhered to protocol actually had an average of 
7.6 millisecond reduction in conduction latency of the optic nerve with 
opicinumab compared to control, but at p = 0.050, it missed the statistical 
significance threshold pre-set for the trial (Cadavid et al., 2017). A follow-up VEP 
measure was taken 8 weeks later, outside of the primary endpoint parameters for 
pre-determined success of the clinical trial, where now patients on opicinumab 
had an average 9.1 millisecond reduction in latency and statistical significance 
was achieved with p = 0.011 (Cadavid et al., 2017). In June of 2016, Biogen 
issued a press release that a combination therapy trial with interferon-beta-1a 
(Avonex) in largely RRMS did not meet primary endpoint of 
cognitive/neurophysical improvement defined by an aggregate score from 
several tests (ClinicalTrials.gov NCT01864148), but a complete written report is 
still pending. An unofficial report compiled largely from poster presentations at 
scientific meetings suggested that subgroup analyses showed that the two lower 
doses showed efficacy in patients younger than 40, patients with RRMS, or 
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disease duration of less than 8 years (Ruggieri et al., 2017). Currently another 
combination therapy trial in largely RRMS is recruiting (ClinicalTrials.gov  
NCT03222973; any of the following anti-inflammatory treatments can be 
combined: interferon-beta, natalizumab, dimethyl fumarate).  
 Thus, the cuprizone and lysolecithin models of remyelination have been 
informative in developing therapeutics in several cases for human demyelinating 
diseases where addressing remyelination is a question. 
 
iii. Kallikrein 6 in Animal Models of Oligodendrocyte Demyelination & 
Remyelination 
 Modulation of KLK6 (also known as protease M, neurosin, or 
myelencephalon-specific protease) expression has been characterized in several 
models of altered myelination. One study used the cuprizone model of mature 
oligodendrocyte toxicity to induce demyelinaton. This study demyelinated the 
corpus callosum for seven days with 0.7% cuprizone and then removed the toxin, 
allowing for seven days of remyelination (Bando et al., 2006). KLK6 expression, 
along with mature oligodendrocyte gene MBP expression, decreased during the 
demyelination period and increased during the remyelination period (Bando et 
al., 2006). While levels of KLK6 and MBP were similar in a non-demyelinated 
control cohort in their study, after 5-7 days of remyelination post-treatment with 
cuprizone, their data suggests KLK6 levels of expression are higher than MBP 
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levels (Bando et al., 2006). It should be noted that this concentration of cuprizone 
is generally higher than typically used in the literature, and the duration of 
demyelination and remyelination are also shorter than typically examined. 
 Another study demonstrated that KLK6 itself can cause demyelination. 
KLK6 was injected in the dorsal funiculus of the spinal cord and induced a two-
fold larger lesion and a 20% loss of oligodendrocytes over 72 hours compared 
vehicle injection (Burda et al., 2013). 
 KLK6 expression has been characterized in EAE models of immune-
induced demyelination. Terayama et al. demonstrated that expression of KLK6 
was highest at the same time of highest clinical severity of behavioral symptoms 
in the EAE MOG35-55 model (Terayama et al., 2005). They also noted that there 
was more expression of KLK6 around EAE lesions in spinal cord, but that it was 
not exclusive to white matter (Terayama et al., 2005). In co-labeling experiments 
they saw that some KLK6 positive cells were of oligodendroglial lineage but that 
there were other cell types positive for KLK6 that they did not identify (Terayama 
et al., 2005). Application of exogenous KLK6 in an EAE MOG35-55 model 
increased pro-inflammatory markers (e.g.IL-17, TNF), inhibited anti-inflammatory 
markers (e.g. IL-4, IL-5) and stimulated earlier onset of dysfunctional motor 
behavior compared to the EAE model on its own (Yoon and Scarisbrick, 2016). 
 Another group used a slightly different model, EAE PLP139-151, but 
confirmed high endogenous KLK6 expression at a similar time after induction of 
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immune response as the MOG35-55 model (Blaber et al., 2004; Terayama et al., 
2005). Additionally, they peripherally immunized animals with rat KLK6 either at 
the same time of EAE induction or prior to EAE induction. They found that KLK6 
protein expression co-localized with T cell and macrophage markers in EAE mice 
21 days after induction (higher clinical severity) but not at 12 days (lower clinical 
severity) (Blaber et al., 2004). Immunization at either time point delayed 
manifestation of clinical symptoms 3-4 days, decreased symptom severity, and 
reduced white matter pathology and inflammation by histology (Blaber et al., 
2004). They also demonstrated that activation of T cells increases their KLK6 
mRNA expression (Blaber et al., 2004). 
 It has also been shown that induction of EAE MOG35-55 in KLK6 knockout 
mice have less severe clinical pathology (mostly tail weakness and not hind limb 
paralysis) and delayed onset of motor dysfunction, decreased BBB permeability 
(peripherally injected Evans blue dye did not extravasate) (Bando et al., 2018). 
About 10% less demyelination in perivascular areas in EAE spinal cord was 
observed in KLK6 knockout mice induced using EAE MOG35-55 compared to EAE 
MOG35-55 induced wildtype animals (Bando et al., 2018). Less peripheral 
infiltrating CD45+ cells were observed (Bando et al., 2018). Further, treatment 
with a KLK6-neutralizing antibody reduced microgliosis and MMP9 expression in 
spinal cord that addition of exogenous KLK6 in the EAE MOG35-55 enhanced 
(Bando et al., 2018).  
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 One study characterized KLK6 levels in the TMEV model of inflammation-
derived progressive demyelination. In brain, TMEV increased levels of KLK6 
RNA expression by 2.5-fold seven days post-induction (acute phase), then 
returned to control levels until day 120 (where there was a 2-fold increase), but 
then returned to control levels by day 180 (Scarisbrick et al., 2012b). In spinal 
cord, KLK6 levels were increased at day 7 post-induction (2-fold), then peaked 
around day 90 (5-fold), and returned back to control levels at day 180 
(Scarisbrick et al., 2012b). When they pre-administered KLK6-neutralizing 
antibody for 5 weeks before inducing the TMEV model of inflammation-derived 
progressive demyelination white matter pathology and microgliosis in spinal cord 
was reduced compared to control at 40 days post-induction, but there was no 
difference with treatment at 180 days (Scarisbrick et al., 2012b). 
 The study of potential therapeutics via inhibition of the KLK6 pathway in 
animal models of MS has been limited to models in which inflammation drives 
myelin pathology. This presents difficulty in determining whether inhibition of the 
KLK6 pathway enables remyelination or if it prevents or hinders inflammation that 
leads to further demyelination. Chapter three of this work focuses on examining 
whether KLK6 pathway inhibition impacts remyelination following demyelination 
in the mouse corpus callosum using the toxin cuprizone. Small molecule 
inhibitors to KLK6 and PAR1 are used that have not been previously tested in 
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any animal model of MS. Histologic assessment of the anterior body of the 
corpus callosum is conducted to determine if KLK6 pathway inhibition after 
cuprizone demyelination alters myelin load or presence of cell types involved in 
the remyelination process, such as OPCs, microglia, and astrocytes. 
b) Methods 
i. KLK6 Inhibition Study in Cuprizone Demyelination Animal Model 
1. Subjects 
 Eight to nine week-old male C57BL6 mice (#664, Jackson Laboratories) 
were treated for 7 weeks with 0.2% Cuprizone formulated as a custom mouse 
diet (TD.170070, Envigo) or vehicle (normal, Purina 5053) diet. After 7 weeks, 
half of the animals were perfused with phosphate-buffered saline; brains were 
collected and fixed with 4% paraformaldehyde (demyelination cohort). The 
remaining cohort (remyelination cohort) was divided into vehicle and KLK6 
inhibitor groups and switched to normal chow (see below for osmotic minipump 
implantation and lateral ventricle cannulation). At the end of two weeks, samples 
were processed to paraffin block. In addition, plasma and brain samples 
collected for pharmacokinetic analysis. All procedures performed on these 
animals were in accordance with regulations and established guidelines and 
were reviewed and approved by the Institutional Animal Care and Use 
Committee. 
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2. Osmotic minipump delivery of KLK6 inhibitor via lateral ventricle cannulation 
 During the seventh week of cuprizone chow administration, mice were 
cannulated in the lateral ventricle (1.0 mm lateral from Bregma, -0.4 mm 
posterior from Bregma, and -2.2 mm ventral from skull). At the same time, an 
osmotic minipump (Alzet #2002; capable of delivering ~0.5 uL/hour for fourteen 
days) was implanted subcutaneously on the body and connected to the cannula 
via catheter (Brain infusion kit 3, Alzet). Pumps were pre-primed with vehicle 
[20% (v/v) PEG 400 / 80% (v/v) of 12.5% SBECD in deionized water, with pH 
between 6.6-7.4] or 7 mM (3.84 mg/mL) KLK6 inhibitor [table 1, item 5 within 
(Liang et al., 2012a)] in vehicle overnight at 37 degrees Celsius the day prior to 
surgery. The final average concentration of the KLK6 inhibitor delivered to the 
brain is expected to be around 2.7 μM in the area of delivery based on exposure 
and estimated protein binding.  
 
3. Histology 
 Brains were processed to paraffin (TissueTek VIP6, Sakura) and then 
sectioned at 5 µm thickness in the region of interest, the anterior body of corpus 
callosum, in a twenty microscope slide series (e.g. first slide contains 1st and 21st 
sections). The 5th and 15th slides (4 sections per animal) were selected for 
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staining with luxol fast blue (Acros Organics 212171000, CAS 1328-51-4). The 
luxol fast blue (LFB) staining solution was made with 0.1g LFB and 0.5mL glacial 
acetic acid per 100 mL 95% ethanol. The sections were hydrated to water 
through xylenes and graded alcohols, then incubated in this LFB staining solution 
for several hours at 42 degrees Celsius. Afterwards, the sections were rinsed in 
water followed by ~10 seconds in 50 mg lithium carbonate (Sigma-Aldrich 62470, 
CAS 554-13-2) per 100 mL distilled water.  Sections were then dehydrated 
through gradient ethanol to xylene and coverslipped using a xylene-based 
mounting medium. Images were acquired using a Zeiss Axioscan Z1 microscope 
and analyzed by a binary assessment of pixels stained over area analyzed using 
a custom macro designed and run using the Visiopharm image analysis platform 
(version 6.9.2.3050; www.visiopharm.com). Statistical analysis was done by 
either an unpaired, two-tailed t-test (demyelination cohort) or a one-way ANOVA 
with Tukey post-hoc comparisons (remyelination cohort).  
 
ii. PAR1 Inhibition Study in Cuprizone Demyelination Animal Model 
1. Subjects 
 Eight to ten week-old male C57BL6 mice (#664, Jackson Laboratories) 
were treated for 7 weeks with 0.2% Cuprizone formulated as a custom mouse 
diet (TD.170070, Envigo) or vehicle (normal, Purina 5053) diet. After 7 weeks, 
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half of the animals were perfused with phosphate-buffered saline; brains were 
collected and fixed with 4% paraformaldehyde or frozen with liquid nitrogen for 
biochemical/gene expression experiments (demyelination cohort). The remaining 
cohort (remyelination cohort) was switched to normal chow. At the same time, 
they were divided and split to vehicle (5% DMSO, 5% Kolliphor, 0.9% w/v saline) 
or 50 mg/kg PAR1 inhibitor (Q94 hydrochloride, Tocris 4755) groups and dosed 
twice a day for 2 weeks, subcutaneously. At the end of two weeks, samples were 
processed the same as above, in addition to plasma and brain samples collected 
for pharmacokinetic analysis. All procedures performed on these animals were in 
accordance with regulations and established guidelines and were reviewed and 
approved by the Institutional Animal Care and Use Committee. 
 
2. Histology 
  Brains were processed to paraffin (TissueTek VIP6, Sakura) and then 
sectioned at 5 µm thickness in the region of interest, the anterior body of the 
corpus callosum, in a twenty microscope slide series (e.g. first slide contains 1st 
and 21st sections). The 5th and 15th slides (4 sections per animal) were selected 
for staining with luxol fast blue (Acros Organics 212171000, CAS 1328-51-4). 
The luxol fast blue (LFB) staining solution was made with 0.1g LFB and 0.5mL 
glacial acetic acid per 100 mL 95% ethanol. The sections were incubated in this 
solution for several hours at 42 degrees Celsius. Then, sections were rinsed in 
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water followed by ~10 seconds in 50 mg lithium carbonate (Sigma-Aldrich 62470, 
CAS 554-13-2) per 100 mL distilled water.  Sections were rinsed in water and 
then dehydrated quickly through gradient ethanol to xylene and coverslipped 
using a xylene-based mounting medium. Images were acquired using a Zeiss 
Axioscan and analyzed by binary assessment of pixels stained over area 
analyzed using a custom macro designed and run using the Visiopharm image 
analysis platform (version 6.9.2.3050; www.visiopharm.com). Statistical analysis 
was done by either an unpaired, two-tailed t-test (demyelination cohort) or an 
one-way ANOVA with Tukey post-hoc comparisons (remyelination cohort). 
 
3. Immunohistochemistry 
Four equally-spaced sections were chosen per immunohistochemical stain and 
hydrated from xylene through graded alcohols to water. Antigen retrieval was 
performed using a Biocare Decloaker (120 degrees Celsius for 30 seconds, 84.5 
degrees Celsius for 10 seconds) in citrate buffer (Biogenex). Sections were 
blocked in normal serum raised to the host species of the secondary antibody for 
an hour, then incubated with primary antibody overnight (see Table 4) at 4 
degrees Celsius. A fluorescent secondary antibody directed to the host species 
of the primary antibody (AlexaFluors, LifeTechnologies) was applied for 1.5 hours 
at room temperature following a few washes with phosphate-buffered saline, and 
counterstained with DAPI (LifeTechnologies). Images were acquired using a 
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Zeiss Axioscan Z1 microscope and analyzed using custom macros designed and 
run using the Visiopharm image analysis platform (version 6.9.2.3050; 
www.visiopharm.com). Statistical analysis was done by either an unpaired, two-
tailed t-test (demyelination cohort) or a one-way ANOVA with Tukey post-hoc 
comparisons (remyelination cohort). 
 
5. UPLC-MS/MS Pharmacokinetic Analysis of PAR1 and KLK6 Inhibitors 
 Plasma and brain samples were analyzed by liquid chromatography–
tandem mass spectrometry (LC-MS/MS). Brain samples were prepared for 
analysis by adding four volumes of 60:40 isopropanol and homogenized using 2 
mm zirconia beads (BioSpec) and 2 minutes of shaking in a bead beater 
(BioSpec).  Analytical standards for each analyte were prepared by solubilizing 
powder stocks into 1:1 DMSO:ACN and standard curves were prepared in naïve 
animal plasma. Brain samples were prepared separately from plasma samples, 
using a mixed matrix approach where an equal volume of naïve brain 
homogenate was added to all standards and an equal volume of naïve plasma 
was added to samples.  Samples were extracted using protein precipitation with 
~5 volumes of an internal standard cocktail (verapamil at 2.5 ng/ml and 
terfenadine at 30 ng/ml) in acetonitrile. Sample blocks were vortexed for 30 
seconds and centrifuged at 3,000 rpm for 5 minutes and ~50 μL of the 
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supernatant was diluted into three volumes of water containing 0.1% formic acid 
for injection onto the LC-MS. 
 Chromatography was performed on a Waters Acquity iClass UPLC 
System (Milford, MA). The autosampler and column were kept at at 10°C and 
40°C, respectively.  Separation was achieved with an Acquity UPLC HSS T3 
column (2.1x50mm, 1.8 µm), and a gradient of 0.1% formic acid in water (Mobile 
Phase A) and 0.1% formic acid in acetonitrile (Mobile Phase B) at a flow rate of 
0.600 mL/min. An initial mobile phase composition of 5% B was ramped to 95% 
over 2 minutes, held at 95% for 0.3 minutes, and then returned to initial 5% B for 
re-equilibration.  
 Data was collected on an AB Sciex API6500 mass spectrometer (Foster 
City, CA, USA) using positive Turbo IonSpray™ electrospray ionization (ESI) and 
multiple reaction monitoring (MRM) mode. Typical source conditions, heated 
capillary temperature, gas1, gas2, and curtain gas were set at 500ºC, 40, 60 and 
30 respectively.  MRM transitions for each analyte, including DP and CE, were as 
follows: KLK6 inhibitor 54991 DP:110 CE:75; PAR1 inhibitor 333125 DP:85 
CE:36. Verapamil was used as the internal standard for the KLK6 inhibitor (MRM 
transitions = 455165 DP:80 CE:30). Terfenadine was used as the internal 
standard for the PAR1 inhibitor (MRM transitions = 472436 DP:80 CE:30). 
Data acquisition and processing was carried out with Analyst software version 
1.6.2. (Applied Biosystems/MDS Sciex, Canada) 
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6. Determination of Compound Fraction Unbound via Equilibrium Dialysis 
 Equilibrium dialysis experiments were conducted in an HTD 96 device 
obtained from HTDialysis, LLC (Gales Ferry, CT).  Prior to the experiment, 
cellulose dialysis membranes (HTDialysis, LLC, MWCO 12-14K) were soaked in 
de-ionized water for 15 minutes, 30% ethanol/de-ionized water for 15 minutes, 
and Dulbecco’s phosphate buffered saline [DPBS; BioWhittaker, #17-512Q] for 
15 minutes or overnight. CD-1 mouse plasma and Wistar-han rat brains were 
obtained from BioreclaimationIVT, LLC (Hicksville, NY).  Mouse plasma was 
thawed at 37°C in a water bath or incubator then pH adjusted to 7.4 with 1 N 
hydrochloric acid.  Rat brain tissue was homogenized prior to use in DPBS (1:10 
tissue: PBS dilution) at RT with an Omni TH tissue homogenizer (Omni 
International, Kennesaw, GA). A probe (7 x 110 mm) was used for 30-second 
pulses at high speed.  The dialysis device was assembled following the 
instructions from the manufacturer (http://www.htdialysis.com). Compound stock 
solutions were prepared at 4 mM in dimethylsulfoxide (DMSO) then diluted 200 
µM in DMSO.  Compound was added to matrices (1:100 dilution) and mixed well 
for a final test compound concentration of 2 µM and 1% DMSO.  To calculate 
stability and recovery for each test compound, a T0 sample of each matrix (15 
µL) was immediately collected into a 96-well plate, mixed with 45 µL of DPBS, 
and crashed with 200 µL of cold acetonitrile containing IS (IS; a cocktail of 5 
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ng/ml terfenadine and 0.5 ng/ml tolbutamide).  For the fraction unbound 
determination, an aliquot (150 µL, n=4 per compound) of spiked matrix (plasma 
or brain homogenate) was added to the donor side of the membrane in the 
dialysis device and blank DPBS (150 µL) was added to the receiver side of the 
membrane.  The dialysis device was sealed with Breathe-Easy Membranes 
(Sigma-Aldrich) before being incubated in a humidified incubator (75% relative 
humidity, 5% CO2/95% air) at 37°C for 6 hours at 200 rpm with an orbital shaker. 
Upon completion of the incubation, matrix samples (15 µL) from the donor wells 
were added to 45 µL of DPBS in a 96-well plate.  Dialyzed DPBS (45 µL) from 
the receiver wells was added to the blank matrix (15 µL).  Samples were crashed 
in acetonitrile as mentioned above for T0 recovery and stability samples. The 
samples were vortexed for 3 minutes (VWR) and centrifuged at 3000 rpm for 5 
minutes at RT. The supernatant was transferred and analyzed by LC-MS/MS. 
Sertraline was used on every incubation plate for quality control. 
Chromatography was performed on a Waters Acquity iClass UPLC System 
(Milford, MA).  Separation was achieved with an Acquity UPLC BEH C18 
(2.1x50mm, 1.7 µm) [PAR1 inhibitor] , and kinetex C18 (30x 2.1mm, 2.6µm) 
[KLK6 inhibitor] and a gradient of 0.1% formic acid in water (Mobile Phase A) and 
0.1% formic acid in acetonitrile (Mobile Phase B) at a flow rate of 0.500 mL/min. 
An initial mobile phase composition of 5% B was ramped to 95% over 2 minutes, 
held at 95% for 0.5 minutes, and then returned to initial 5% B for re-equilibration 
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for the PAR1 inhibitor. For the KLK6 inhibitor, it was ramped to 95% over 1.2 
minutes, held at 95% for 0.4 minutes, and then returned to initial 5% B for re-
equilibration. Data was collected on an AB Sciex API6500 mass spectrometer 
(Foster City, CA, USA) using positive Turbo IonSpray™ electrospray ionization 
(ESI) and multiple reaction monitoring (MRM) mode.  Typical source conditions, 
heated capillary temperature, gas1, gas2, and curtain gas were set at 500 ºC, 40, 
60 and 30 respectively.  MRM transitions for each analyte, including DP and CE, 
were as follows: KLK6 inhibitor 54991 DP:110 CE:50; PAR1 inhibitor 333125 
DP:85 CE:36. Data acquisition and processing was carried out with Analyst 
software version 1.6.2. (Applied Biosystems/MDS Sciex, Canada). 
 
c. Results 
 Pharmacokinetic study of the KLK6 inhibitor used previously for in vitro 
experiments was done at 0.5, 2, 8, and 24 hours post-administration by 
subcutaneous injection in mouse. One key objective was to determine if the 
compound was likely to be brain penetrant following this administration route. 
Exposure levels of compound were measured in plasma and brain at two 
concentrations of the inhibitor: 10 mg/kg & 50 mg/kg. The KLK6 inhibitor was not 
readily brain penetrant at either concentration tested (Figure 3 C-D). The KLK6 
inhibitor was also found to bind highly in brain (Table 5). Thus, to investigate the 
impact of the KLK6 inhibitor in an in vivo remyelination model, a chronic osmotic 
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pump delivery method cannulated into the lateral ventricle was used with the 
highest concentration with parameters compatible with the dosing paradigm (37 
degrees C for 14 days). Pharmacokinetic analysis from lateral ventricle 
cannulated osmotic pump animals receiving KLK6 inhibitor for 14 days indicate 
the drug was present in brain (cerebellum), cerebrospinal fluid, and plasma 
(Figure 3E). 
 Next, a seven week paradigm of ad libitum 0.2% cuprizone chow 
administration was used to induce demyelination of the corpus callosum in 
C57BL6/J mice. During the seventh week, cuprizone chow was removed upon 
implantation of a subcutaneous osmotic pump pre-primed with KLK6 inhibitor (or 
vehicle) that was cannulated for intracerebroventricular delivery into the lateral 
ventricle. After 14 days of continuous administration the animals were euthanized 
and samples were collected for analysis. Demyelination was induced in the 
corpus callosum after seven weeks of cuprizone treatment, as indicated by a 
decrease in luxol fast blue staining (Figure 4 A-B, G). Cuprizone withdrawal and 
replacement with normal chow naturally spurred spontaneous remyelination in 
cuprizone/vehicle animals, as indicated by a smaller percentage change 
difference in luxol fast blue staining compared to animals that only received 
normal chow (Figure 4 C-D, H). Compared to cuprizone/vehicle, luxol fast blue 
staining in cuprizone/KLK6i treated animals demonstrated 16% more myelination 
in the corpus callosum (Figure 4 D-F, H). Immunohistochemical staining for the 
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CC1 clone of APC which stains mature oligodendrocytes demonstrated that 7 
weeks of cuprizone decreases CC1 staining by 30% in mouse corpus callosum 
(Figure 5 A-B, G). The effects of spontaneous remyelination observed with luxol 
fast blue was corroborated by a large increase in corpus callosum CC1 staining 
in animals in which cuprizone chow was withdrawn compared to cuprizone naïve 
animals (Figure 5 C-D, H). Cuprizone/KLK6i treated animals demonstrated a 
19% increase in corpus callosum CC1 staining compared to cuprizone/vehicle 
animals, but the result did not achieve statistical significance at p = 0.11 (Figure 
5 D-F, H).  
 The cuprizone model paradigm employed also induced a significant 
neuroinflammation in the corpus callosum. Astrogliosis, indicated by gain in 
GFAP+ staining, was increased 660% with cuprizone treatment (Figure 6 A-B, 
G). Microgliosis, indicated by gain in Iba1+ staining, was increased by 25% with 
cuprizone treatment (Figure 7 A-B, G). Two weeks after cuprizone withdrawal, 
less inflammation was observed in the corpus callosum, via GFAP and Iba1 stain 
reductions, in the cuprizone/vehicle condition (Figure 6 C-D, H; Figure 7 C-D, 
H). Cuprizone/KLK6i treated animals had a further reduction in GFAP+ stain in 
corpus callosum, a 19% decrease, compared to cuprizone/vehicle (Figure 6 D-F, 
H). In contrast, no change was seen in the corpus callosum of curpizone/KLK6i 
treated animals compared to vehicle with Iba1+ staining (Figure 7 D-F, H). No 
differences in oligodendrocyte precursor cells were identified in the corpus 
82 
 
 
callosum upon cuprizone treatment or with KLK6i treated after cuprizone 
withdrawal (Figure 8 A-H). 
 Pharmacokinetic analysis of the PAR1 inhibitor was done in mouse at 0.5, 
2, 8, and 24 hours after subcutaneous injection to determine if the compound 
was likely to be brain penetrant (measured by exposure levels in plasma and 
brain at two concentrations of the inhibitor- 10 mg/kg & 50 mg/kg). The PAR1 
inhibitor was found to be brain penetrant at both concentrations tested (10 and 
50 mg/kg), with an estimated duration of eight hours before drug concentration 
significantly diminishes (Figure 5 A-B). The PAR1 inhibitor was also found to 
bind highly in brain (Table 5). 
 A seven-week duration of 0.2% cuprizone administration to C57Bl6/J mice 
was used to establish demyelination and to test the remyelination potential of the 
brain penetrant PAR1 inhibitor. At seven weeks, a portion of the animals were 
collected as part of a demyelination cohort for analysis. The cohort for 
remyelination analysis discontinued cuprizone treatment at this time and began 
administration of vehicle or PAR1 antagonist (50mg/kg, BID, SC). 
 Data from the demyelination cohort of the cuprizone study demonstrates 
the baseline of demyelination at which drug administration began. Using luxol 
fast blue staining and a custom positive pixel per area analyzed algorithm, a 
forty-five percent reduction in myelinated fibers in the anterior body of the corpus 
callosum was seen in the seven-week, 0.2% cuprizone treated animals 
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compared to vehicle animals (Figure 9 A ,B, G). This indicates significant 
demyelination has occurred in the corpus callosum with the cuprizone paradigm. 
This model thus allows for a maximum of forty-five percent recovery of 
myelination from baseline before drug administration, excluding rate of 
spontaneous remyelination. 
 In the remyelination cohort, collected two weeks later after PAR1 or 
vehicle administration, only a twenty-five percent reduction in myelinated fibers in 
the anterior body of the corpus callosum existed between vehicle/naïve and 
cuprizone/vehicle-treated animals (representative images, Figure 9 C-D, H). This 
indicates, as expected for the model, spontaneous remyelination has taken place 
in the two weeks in which cuprizone was removed from the mouse diet during the 
vehicle or drug treatment portion of the remyelination study. No statistically 
significant changes in myelinated fibers were detected between the 
cuprizone/vehicle and cuprizone/PAR1 inhibitor treated animals in the anterior 
body of the corpus callosum (representative images, Figure 9 D-F, H).  This 
suggests that the PAR1 inhibitor treatment paradigm did not have a larger impact 
on remyelination compared to the level of spontaneous remyelination in the 
model. 
 Immunohistochemical staining for NG2, a chondroitin sulfate proteoglycan 
present on later-stage oligodendrocyte precursor cells, also demonstrated no 
statistically significant differences in percent stained area across treatment 
84 
 
 
groups in the anterior body of the corpus callosum (Figure 10 A-H) or in the 
cingulate cortex (Figure 10 I-M). 
 Cuprizone treatment induced microgliosis and astrogliosis, as indicated by 
a 163% increase in Iba1 immunohistochemical stain (Figure 11 A-B, G) or 409% 
increase in GFAP immunohistochemical stain (Figure 12 A-B, G), respectively, 
in the corpus callosum. Two weeks of PAR1 inhibitor treatment paradigm did not 
result in a reduction of Iba1 or GFAP compared to vehicle treatment (Figure 11 
C-F, H; Figure 12 C-F, H). 
d. Discussion 
 Compared to other animal models of demyelination, the cuprizone model 
of demyelination is not etiologically created by immune dysfunction and allows for 
direct study of an agent on remyelination as opposed to inflammation. Chapter 
three of this work uses the cuprizone model of demyelination to examine the role 
of KLK6 pathway inhibition on remyelination in a mammalian species in vivo 
using specific inhibitors that have not previously been described with the 
cuprizone model. 
 Cuprizone administration in chow for seven weeks resulted in 30-45% 
demyelination in the rostral corpus callosum as assessed by luxol fast blue 
myelin stain. Pharmacological intervention in the cuprizone model has been 
previously demonstrated to have the largest window for efficacy at 2-3 weeks 
post-withdrawal of cuprizone using very similar demyelination parameters 
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(Deshmukh et al., 2013; Li et al., 2015). Spontaneous remyelination continues to 
occur as time passes post-cuprizone withdrawal (reducing dynamic range to see 
an efficacious impact). As expected, during the two weeks post-demyelination in 
which treatment was evaluated compared to vehicle, animals treated with 
cuprizone experienced some degree of spontaneous remyelination. Thus, in 
order to be efficacious in the model, the treatments need to be more efficient or 
faster at inducing myelination compared to spontaneous remyelination due to 
cuprizone withdrawal and an acute cuprizone treatment paradigm. 
 In order to evaluate brain penetrance and clearance, pharmacokinetic 
evaluation was conducted using subcutaneous administration for the KLK6 
inhibitor and the PAR1 inhibitor used in in vitro oligodendrocyte maturation 
assays in chapter 2.  Pharmacokinetic analysis of the PAR1 inhibitor 
demonstrated plasma and brain exposure following subcutaneous administration. 
The profile of clearance over time suggested a minimum of twice a day dosing at 
the highest concentration tested to engage the target for the majority of a given 
day.  Pharmacokinetic analysis of the KLK6 inhibitor following subcutaneous 
administration demonstrated plasma exposure but virtually no brain exposure at 
the concentrations tested. Thus, the PAR1 inhibitor is easily incorporated into an 
evaluation of remyelination using the cuprizone model of demyelination. 
However, evaluating the effect of KLK6 inhibition on remyelination via cuprizone 
model of demyelination is more complicated. While the KLK6 inhibitor increased 
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oligodendrocyte maturation with direct application in vitro, it would not be able to 
reach the target cell types in the brain using conventional dosing methods. Given 
the lack of KLK6 inhibitor brain penetrance, options for administering the KLK6 
inhibitor directly into the central nervous system under subchronic conditions 
were researched. Options were assessed for feasibility based on compound 
properties such as solubility and stability. A chronic intracerebroventricular 
infusion method via cannulated osmotic minipump (Alzet) was selected to deliver 
the KLK6 inhibitor into the lateral ventricle within the brain in a continuous, 
subchronic fashion. Direct-into-the-brain injection was ruled out due to the length 
of dosing (14 days) and the potential for the cannula to clog if situated directly in 
brain tissue due to tissue remodeling and the lipid-rich region of interest. One 
caveat with ICV injection delivery is that the compound will still need to cross 
from the cerebrospinal fluid into the brain to reach the target cells. Although 
stereotaxic surgery involved in this method of administration (cannula 
implantation) creates acute disruption in the blood-brain barrier, it is unlikely to 
impact demyelination and remyelination outcomes (Tejedor et al., 2017). 
However, administration of opioids and non-steroidal anti-inflammatories, used 
for surgical treatment-related comfort of the animal, may have the potential to 
induce remyelination (Eschenroeder et al., 2012; Preisner et al., 2015). 
 The concentration of KLK6 inhibitor was maximized according to solubility 
in an osmotic-pump compatible vehicle where it would be also stable for >14 
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days at 37 degrees Celsius (data not shown) and to account for non-specific 
protein binding estimates. At the end of a seven week demyelination period using 
0.2% cuprizone chow, animals were equipped with an osmotic pump filled with 
KLK6 inhibitor or vehicle which was catheterized to a lateral ventricle cannula. 
After 14 days of treatment, pharmacokinetic analysis of plasma, CSF, and 
cerebellum indicated that exposure was achieved in all compartments and even 
in brain tissue far away from the injection site. Due to protein binding estimates, it 
is expected that the compound is at higher concentration closer to the injection 
site. 
 Assessment of myelin by luxol fast blue staining demonstrated a 16% 
increase in corpus callosum myelination after two weeks cuprizone 
withdrawal/concurrent KLK6 inhibitor treatment when compared to vehicle. This 
degree of remyelination is similar to levels previously published with alternate 
mechanisms (Deshmukh et al., 2013). Additionally, KLK6 inhibitor treatment 
resulted in 19% decreased GFAP-positive astrocyte stained area in the corpus 
callosum compared to vehicle treatment after cuprizone. CC1 staining for mature 
oligodendrocytes post-cuprizone withdrawal reflected an increase with 
spontaneous remyelination/oligodendrocyte differentiation, but the 19% increase 
between cuprizone/vehicle and cuprizone/KLK6i treatments did not reach 
statistical significance (p = 0.11). No changes were seen in Iba1-positive 
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microglia stained area or NG2-positive OPC stained area in the corpus callosum 
with KLK6 inhibitor treatment post-cuprizone withdrawal. 
 Thus, this experiment is the first example of a small molecule KLK6 
inhibitor to demonstrate enhanced myelination following the non-immune 
mediated cuprizone model of demyelination. Further, the reduction in astrocyte 
but not microglia staining suggests a dual effect of KLK6 inhibition on 
oligodendrocytes and astrocytes, or may signify a role for astrocytic regulation of 
myelination via KLK6. Previous work has demonstrated that KLK6 protein is 
found within reactive, hypertrophied astrocytes in a variety of diseases 
(Scarisbrick et al., 2012a). This is in contrast to in vitro RNA sequencing data 
which suggests KLK6 is only present in oligodendrocytes, and not astrocytes 
(Zhang et al., 2014; Zhang et al., 2016). However, the latter work was done on 
cells in their basal state, not an activated state. 
  
 To investigate whether the inhibition of downstream signaling molecule 
activated by KLK6 could also enhance myelination in vivo post-cuprizone 
treatment, a brain-penetrant PAR1 inhibitor was also tested. The PAR1 inhibitor 
was dosed subcutaneously at 50 mg/kg concentration, dosed twice a day for 14 
days following cuprizone withdrawal. No difference in myelination was seen by 
luxol fast blue staining in the corpus callosum of animals treated with a PAR1 
inhibitor compared to vehicle treatment for 2 weeks post-cuprizone withdrawal. 
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Further, no difference was also seen with KLK6 inhibitor treatment related to 
NG2-positive OPCs. Cuprizone treatment itself is not expected to impact OPC 
population, which was corroborated with our data. However, if the remyelination 
was not complete enough to be seen by LFB but currently in progress when the 
samples were collected, it is reasonable to expect an increase in OPCs around 
the callosal region (corpus callosum and cingulate cortex above corpus callosum 
were analyzed) in the PAR1 inhibitor treatment group but not the vehicle treated 
group. In both regions there were similar levels of NG2-positive percent area 
stain per area measured in the PAR1 inhibitor treatment group as vehicle. This 
evidence corroborates the luxol fast blue results and similarly conveys that the 
PAR1 inhibitor did not accelerate maturation leading to successful myelination 
differentially vehicle. No difference was also seen with GFAP-positive astrocyte 
staining or Iba1-positive microglial staining upon KLK6 inhibition. 
This overall result is somewhat surprising given previous findings that PAR1 
inhibition can mature OPCs in vitro (Yoon et al., 2015), however, the results of 
this experiment corroborate the in vitro result in chapter 2 of this work. 
 Based on our pharmacokinetic profile, it is confirmed that the PAR1 
inhibitor is brain penetrant and thus has access to the brain to mediate direct 
mechanisms of therapeutic intervention in the brain. No overt adverse events 
were associated with this concentration, exposure, and duration of treatment with 
PAR1 inhibitor in mice in this study.  This is the first attempt of in vivo 
90 
 
 
administration of this particular PAR1 inhibitor (IC50 = 10-100nM), which is 
expected to have better brain penetration than PAR1 inhibitors used in vitro 
(Burda et al., 2013) or in vivo (Bogovyk et al., 2017) based on chemical structure. 
It is possible that exposure was not consistently high enough to see the 
hypothesized effect on remyelination and the drug should have been dosed three 
times per day.  The process of generating myelin sheaths after differentiation has 
been shown to be restricted to a timeframe as short as five hours post-maturation 
for oligodendrocytes in zebrafish (Czopka et al., 2013). A gap of time longer than 
this existed between each day of treatment. In addition, the amount of protein 
binding estimated to exist in brain may have reduced the amount of compound 
that made it to target cells in the brain. Future studies should focus on 
comparison of SCH79797 and the PAR1 inhibitor used in this study to 
understand the different properties that could impact function. 
 The cuprizone model has previously been used to determine whether 
therapeutic mechanisms are purely related to dampening inflammation or also 
exert direct effects on myelin repair (Hu et al., 2011). It is possible that PAR1 
inhibition may still be beneficial in treating inflammatory components associated 
with disorders of myelin loss like MS, whether or not it directly enhances 
remyelination. Overly active, infiltrating cytotoxic T lymphocytes secrete 
granzyme B in MS, which induces cell death (Neumann et al., 2002; Frischer et 
al., 2009; Bien et al., 2012). PAR1 inhibition has also been shown to prevent T 
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lymphocyte granzyme B neurotoxicity (Lee et al., 2017) and improve recovery 
after spinal cord injury by reducing associated inflammation (Radulovic et al., 
2016). 
 In summary, a novel KLK6 inhibitor was shown to increase remyelination 
in the corpus callosum after cuprizone-mediated demyelination. A reduction in 
astrogliosis in the corpus callosum was also seen with KLK6 inhibition post-
cuprizone. Understanding of current data suggests that perhaps an effect of 
KLK6 inhibition on both cell types could be related to similar lineage origin of 
astrocytes and oligodendrocytes. In this case KLK6 inhibition may be both an 
anti-inflammatory and a pro-myelinating treatment. Another interpretation is that 
the reduction in astrogliosis is reflective of astrocyte modulation of 
oligodendrocytes/myelination and thus the mechanism by which myelination is 
increased with KLK6 treatment. A PAR1 inhibitor, thought to be another method 
of inducing downstream KLK6 inhibition, was not effective at enhancing 
myelination in the corpus callosum post-cuprizone withdrawal. It is suspected 
that despite brain penetrance, other properties of the small molecule may have 
been problematic.  
 Future directions include furthering current understanding of the 
relationship between myelination in response to KLK6 inhibition and reduction in 
astrogliosis in response to KLK6 inhibition. Additionally, this KLK6 inhibitor, or 
one with improved chemical properties, should be tested in a model of 
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progressive demyelination (such as TMEV) by itself and in combination with an 
anti-inflammatory treatment to explore its efficacy in a model most similar to 
human MS. 
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Table 4. Chapter 3 Antibody Information 
 
 
 
Free, unbound fraction of/in: Mouse Plasma Rat Brain 
KLK6 inhibitor 0.0081 0.00038 
PAR1 inhibitor 0.0053 0.0017 
Table 5. Free, unbound fractions of small molecule inhibitors in plasma and brain 
  
Full Name Short 
Name 
Vendor Catalog 
Code 
Host  
Species 
Tissue 
Tested 
Species 
CC-1 clone / 
Adenomatus 
Polyposis Coli 
CC1 Millipore OP80 Mouse Mouse, 
Human 
Glial Fibrillary 
Acidic Protein 
GFAP Dako North 
America 
Z0034 Rabbit Mouse, 
Human 
Ionized calcium-
binding adapter 
molecule 1 
Iba1 Wako 
Chemicals 
019-19741 Rabbit Mouse, 
Human 
Myelin Basic 
Protein 
MBP AbD Serotec MCA409S Rat Mouse, 
Human 
Neural/Glial 
proteoglycan 
antigen 2 
NG2 Millipore AB5320 Rabbit Mouse, 
Human 
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Figure 3. Pharmacokinetic Assessment of Small Molecule Inhibitors 
 
A-B: PAR1 inhibitor concentration in mouse plasma and brain after 
subcutaneous administration of 10mg/kg (red) or 50 mg/kg  (blue) at 0.5, 2, 8, or 
24 hours post-injection. The PAR1 inhibitor was determined to be brain penetrant 
and a dose of 50 mg/kg was selected for an in vivo remyelination model study. 
C-D: The KLK6 inhibitor used for in vitro experimentation is not readily brain 
penetrant when dosed peripherally in a study with same design as described in 
A-B, as demonstrated by pharmacokinetic study in plasma and brain.  
E: KLK6 inhibitor is detectable in brain (cerebellum), cerebrospinal fluid, and 
plasma after 14 days of lateral ventricle cannulated osmotic pump continuous 
delivery (~0.5 µL/hour). All graphs within the figure represent the data as mean 
plus or minus the standard error of the mean. 
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Figure 4. The Effects of KLK6 Inhibition on In Vivo Remyelination 
 
A-B, G: A 30% reduction in corpus callosum myelinated fibers (Luxol Fast Blue) 
is seen in mouse brain after 7 weeks 0.2% cuprizone treatment (cuprizone/naïve, 
C/N) versus normal chow vehicle (normal chow/naïve, N/N). This was quantified 
using a custom algorithm designed in Visiopharm. Statistical analysis was done 
using an unpaired, two-tailed t-test.  
C-F, H: Following 7 weeks 0.2% cuprizone treatment administration, normal 
vehicle chow was resumed for 2 weeks concurrent with continuous 
administration of a KLK6 inhibitor or vehicle via subcutaneously implanted 
osmotic pump cannulated to the lateral ventricle of the brain. Naïve animals that 
never received cuprizone treatment (Normal/Naïve, N/N) were carried along as 
sample processing comparison. Compared to naïve, a 22% reduction was seen 
two weeks post-cuprizone withdrawal in the vehicle group. There was a 16% 
statistically significant increase in myelinated fibers during this time in this portion 
of the corpus callosum between Cuprizone/Vehicle (C/V) and Cuprizone/KLK6i 
(C/P) inhibitor treatment. Representative images from one to two animals per 
group are shown. Quantification was done using a custom algorithm designed in 
Visiopharm. Statistical analysis was done using a one-way ANOVA with Tukey 
post hoc comparisons. Scale bar = 100 µm. All graphs within the figure represent 
the data as mean plus or minus the standard error of the mean. 
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Figure 5. KLK6i Treatment Post-Cuprizone Results in Trend Increase of 
CC1+ Mature Oligodendrocytes 
 
A-B, G: Seven weeks treatment with 0.2% cuprizone induced a 30% decrease in 
area stain of mature oligodendrocytes immunohistochemically detected in the 
corpus callosum using CC1 clone of APC antigen. Quantification was done using 
a custom algorithm designed in Visiopharm. Statistical analysis was done using 
an unpaired, two-tailed t-test.  
C-F, H: Two weeks after the withdrawal of cuprizone administered via the above 
described paradigm, there was a 150% increase in area stained by CC1 in the 
corpus callosum (N/V to C/V), that is likely the result of increased mature 
oligodendrocyte differentiation related to spontaneous remyelination in this 
model. There is a 19% increase in CC1 area stain in corpus callosum between 
cuprizone/vehicle and cuprizone/KLK6i-treated animals, but it did not reach 
statistical significance (p = 0.11). Quantification was done using a custom 
algorithm designed in Visiopharm. Statistical analysis was done using a one-way 
ANOVA with Tukey post-hoc.  
 
CC1 = red; DAPI = blue. Scale bar = 100 µm. All graphs within the figure 
represent the data as mean plus or minus the standard error of the mean. 
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Figure 6. KLK6i Treatment Post-Cuprizone Reduces Astrogliosis 
 
A-B, G: Seven weeks of 0.2% cuprizone treatment induced 660% increase in 
astrogliosis (defined by GFAP+ stain area per area analyzed) in the corpus 
callosum compared to normal/naïve mice. Quantification was done using a 
custom algorithm designed in Visiopharm. Statistical analysis was done using an 
unpaired, two-tailed t-test. 
C-F, H: Two weeks post-cuprizone withdrawal, less astrogliosis was present 
relative to just after 7 weeks of cuprizone treatment. However, there was still a 
223% increase in GFAP+ stain in cuprizone/vehicle compared to normal/vehicle 
animals. After 14 days continuous administration of a KLK6 inhibitor into the 
lateral ventricle, a 19% decrease in GFAP+ stain was seen compared to vehicle-
treated cohort. Quantification was done using a custom algorithm designed in 
Visiopharm. Statistical analysis was done using a one-way ANOVA with Tukey 
post-hoc. 
 
GFAP = red; DAPI = blue. Scale bar = 100 µm. All graphs within the figure 
represent the data as mean plus or minus the standard error of the mean. 
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Figure 7. KLK6i Treatment Post-Cuprizone Does Not Alter Microgliosis 
 
A-B, G: Compared to normal/naïve mice, a 25% increase in Iba1+ stain/area was 
induced with seven weeks 0.2% cuprizone administration in mouse corpus 
callosum. Quantification was done using a custom algorithm designed in 
Visiopharm. Statistical analysis was done using an unpaired, two-tailed t-test. 
 
C-F, H: Two weeks after cuprizone withdrawal, an 18% increase in microgliosis 
(defined by Iba1+ stain/area) persisted in the corpus callosum of 
cuprizone/vehicle treated animals compared to normal/naïve treated. No 
statistically significant difference in Iba1+ stain was found between 
cuprizone/vehicle treated and cuprizone/KLK6i treated animals. Quantification 
was done using a custom algorithm designed in Visiopharm. Statistical analysis 
was done using a one-way ANOVA with Tukey post-hoc. 
 
Iba1 = green; DAPI = blue. Scale bar = 100 µm. All graphs within the figure 
represent the data as mean plus or minus the standard error of the mean. 
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Figure 8. Oligodendrocyte Precursor Cells Are Not Altered by Cuprizone, 
KLK6i Treatment 
 
A-B, G: No statistically significant changes in NG2, a marker of oligodendrocyte 
precursor cells, immunohistochemical staining were present in the corpus 
callosum following seven weeks of 0.2% cuprizone treatment. Quantification was 
done using a custom algorithm designed in Visiopharm. Statistical analysis was 
done using an unpaired, two-tailed t-test. 
 
C-F, H: No statistically significant changes in NG2 immunohistochemical staining 
in the corpus callosum were observed two weeks after cuprizone withdrawal or 
with continuous KLK6 inhibitor infusion into the lateral ventricle. Quantification 
was done using a custom algorithm designed in Visiopharm. Statistical analysis 
was done using a one-way ANOVA with Tukey post-hoc. 
 
NG2 = green; DAPI = blue. Scale bar = 100 µm. All graphs within the figure 
represent the data as mean plus or minus the standard error of the mean. 
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Figure 9. The Effects of PAR1 Inhibition on In Vivo Remyelination  
A-B, G: A 45% reduction in corpus callosum myelinated fibers (Luxol Fast Blue) 
is seen in mouse brain after 7 weeks 0.2% cuprizone treatment (cuprizone/naïve, 
C/N) versus normal chow vehicle (normal/naïve, N/N), quantified using a custom 
algorithm designed in Visiopharm. Statistical analysis was done using an 
unpaired, two-tailed t-test.  
C-F, H: Following 7 weeks 0.2% cuprizone treatment administration, normal 
vehicle chow was resumed for 2 weeks concurrent with subcutaneous 
administration of a PAR1 inhibitor (50mg/kg) or Vehicle. Naïve animals that never 
received cuprizone treatment (Normal/Naïve, N/N) were carried along as sample 
processing comparison. Compared to naïve, a 25% reduction was seen 2 weeks 
post-cuprizone withdrawal in the vehicle group. There was no statistically 
significant change in myelinated fibers during this time in this portion of the 
corpus callosum between Cuprizone/Vehicle (C/V) and Cuprizone/PAR1 (C/P) 
inhibitor treatment. Representative images from one to two animals per group are 
shown. Quantification was done using a custom algorithm designed in 
Visiopharm. Statistical analysis was done using a one-way ANOVA with Tukey 
post hoc comparisons. Scale bar = 100 µm. All graphs within the figure represent 
the data as mean plus or minus the standard error of the mean. 
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Figure 10: Oligodendrocyte Precursor Cells Are Not Impacted By 
Cuprizone, PAR1i Treatment  
 
Oligodendrocyte precursor cells (labeled by the chondroitin sulfate proteoglycan 
protein NG2) in the corpus callosum (A-H) and cingulate cortex (I-M) are not 
impacted by cuprizone treatment nor altered upon PAR1 inhibitor treatment. 
Cuprizone (0.2%) was administered in chow for seven weeks, then withdrawn for 
the 2 week period of remyelination during which a 50 mg/kg PAR1 inhibitor or 
vehicle was administered. A custom algorithm (Visiopharm) was used to assess 
percentage of stained NG2-positive pixels per area over the region of interest 
(cingulate cortex or anterior body of the corpus callosum). Statistical analysis 
was done with either an unpaired, two-tailed t-test or a one-way ANOVA with 
Tukey post-hoc comparisons. 
 
NG2 = green; DAPI = blue. Scale bar = 100 µm. All graphs within the figure 
represent the data as mean plus or minus the standard error of the mean. 
 
 
 
 
109 
 
 
 
K
 
110 
 
 
 
111 
 
 
Figure 11: Astrogliosis Is Induced With Cuprizone Treatment but Is Not 
Modulated Upon Treatment with A PAR1 Inhibitor 
 
A-B, G: An above 400% increase in astrogliosis (as measured by GFAP 
immunoreactivity, red, per area analyzed) was seen in the corpus callosum in 
mouse brain after 7 weeks 0.2% cuprizone treatment (cuprizone/naïve, C/N) 
versus vehicle (vehicle/naïve, V/N), quantified using a custom algorithm designed 
in Visiopharm. Statistical analysis was done using an unpaired, two-tailed t-test.  
C-F, H: Following 7 weeks 0.2% cuprizone treatment administration, vehicle 
chow was resumed for 2 weeks concurrent with subcutaneous administration of a 
PAR1 inhibitor (50mg/kg) or Vehicle. Naïve animals that never received 
cuprizone treatment (Vehicle/Naïve, V/N) were carried along as sample 
processing comparison. A continued above 400% increase in astrogliosis was 
present 2 weeks post-cuprizone withdrawal in the vehicle group compared to 
naive. There was no statistically significant change in astrogliosis in the corpus 
callosum with Cuprizone/PAR1 (C/P) inhibitor treatment compared to 
Cuprizone/Vehicle (C/V). Representative images from one to two animals per 
group are shown. Quantification was done using a custom algorithm designed in 
Visiopharm. Statistical analysis was done using a one-way ANOVA with Tukey 
post hoc comparisons. 
GFAP = red; DAPI = blue. Scale bar = 100 µm. All graphs within the figure 
represent the data as mean plus or minus the standard error of the mean. 
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Figure 12: Microgliosis Is Induced With Cuprizone Treatment but Is Not 
Modulated Upon Treatment with A PAR1 Inhibitor 
A, B, G: An 160% increase in microgliosis (as measured by Iba1 
immunoreactivity) in the corpus callosum is seen in mouse brain after 7 weeks 
0.2% cuprizone treatment (cuprizone/naïve, C/N) versus vehicle (vehicle/naïve, 
V/N), quantified using a custom algorithm designed in Visiopharm. Statistical 
analysis was done using an unpaired, two-tailed t-test.  
C-F, H: Following 7 weeks 0.2% cuprizone treatment administration, vehicle 
chow was resumed for 2 weeks concurrent with subcutaneous administration of a 
PAR1 inhibitor (50mg/kg) or Vehicle. Naïve animals that never received 
cuprizone treatment (Vehicle/Naïve, V/N) were carried along as sample 
processing comparison. A continued above 100% increase in microgliosis was 
present 2 weeks post-cuprizone withdrawal in the vehicle group compared to 
naive. There was no statistically significant change in microgliosis in the corpus 
callosum with Cuprizone/PAR1 (C/P) inhibitor treatment compared to 
Cuprizone/Vehicle (C/V). Representative images from one to two animals per 
group are shown. Quantification was done using a custom algorithm designed in 
Visiopharm. Statistical analysis was done using a one-way ANOVA with Tukey 
post hoc comparisons. 
 
Iba1 = red; DAPI = blue. Scale bar = 100 µm. All graphs within the figure 
represent the data as mean plus or minus the standard error of the mean. 
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CHAPTER FOUR 
Kallikrein 6 in Multiple Sclerosis 
a) Introduction 
 Multiple sclerosis (MS) is a heterogeneous disorder, with patients 
manifesting various combinations of symptoms to varying levels of severity over 
different periods of time. Sub-classification types of MS exist in an attempt to 
further define the patient experience and behavioral representation of disease 
pathology. Relapsing-remitting MS (RRMS) patients cycle through phases of 
disability and remission while progressive MS patients (secondary or primary; 
SPMS, PPMS) increase in disability over time (Stadelmann and Bruck, 2008). 
Diagnosis of MS and characterization of a patient within a sub-classification of 
the disease is based largely on clinical history and assessment by the neurologist 
(Katz Sand, 2015; Thompson et al., 2017). Currently, there are no biomarkers 
available that can specifically assess degree of MS pathology or define subsets 
of MS (Siva, 2018). Magnetic resonance imaging is generally done to examine 
the presence of white matter lesions in the brain, although it does not exclude 
other white matter-affecting disorders (Katz Sand, 2015; Siva, 2018). Through T2 
MRI (with or without gadolinium-contrast agent), gross white matter pathology in 
the brain and spinal cord can be visualized (Katz Sand, 2015). Although this 
measure is not generally used to determine the primary endpoint of clinical 
efficiency in therapeutic-directed clinical trials, perhaps due to current imaging 
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limitations, it is often a measure observed to see if progress has been made. 
Clinical MRI methods are continuously evolving to become more sensitive and to 
have higher resolution (Kilsdonk et al., 2016). 
 Although these measures do not diagnose MS, assessment of CNS 
pathology in MS can be examined in more detail using cerebrospinal fluid and 
blood product samples as well as histological/immunohistochemical analysis of 
brain and spinal cord collected post-mortem (Katz Sand, 2015; Siva, 2018). 
Researchers are currently investigating potential biomarkers in MS CSF and 
plasma/serum (Housley et al., 2015). 
 Kallikrein 6 (KLK6; also known as protease M, neurosin, or 
myelencephalon-specific protease), is a serine protease that has been proposed 
as a biomarker in cancer and neurodegenerative disease (Ruckert et al., 2008; 
Petraki et al., 2012; Seiz et al., 2012; Dukic et al., 2016). Recently, it has been 
found to be increased in MS patients. One study has shown that MS patients 
(with unspecified sub-classification) have around 4 ng/mL higher levels of KLK6 
in their CSF (Hebb et al., 2010). Another has demonstrated that SPMS patient 
serum has ~0.5 µg/L higher KLK6 than in control patients; this same study also 
tested RRMS patients but variability was high across patients (Scarisbrick et al., 
2008). A separate study found an increase in KLK6 of RRMS patient CSF versus 
control when they examined active KLK6 levels (Bando et al., 2018). They also 
reported that MS patients that had received a pulse of steroid treatment (broad 
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anti-inflammatory treatment) had lower levels of KLK6 in CSF compared patients 
who hadn’t (Bando et al., 2018). 
 The presence of KLK6 has also been generally noted within MS plaques 
and around their borders using immunohistochemistry (Scarisbrick et al., 2002). 
RNA sequencing data from rodents and patients without MS suggests that 
expression is primarily in oligodendrocytes out of common cells found within the 
brain in their basal state (Zhang et al., 2014; Zhang et al., 2016). However, other 
cells may express KLK6 in activated states which is supported by reports that 
KLK6 aids in T lymphocyte cell survival and causes astrocytes to become 
reactive (Scarisbrick et al., 2011; Scarisbrick et al., 2012a). In animal models, 
KLK6 has been noted in macrophages and T cells in addition to cells of 
oligodendroglial cell lineage (Blaber et al., 2004; Terayama et al., 2005). 
 The cellular pathology at the level of MS plaque is another diverse aspect 
of the disease and has been categorized into general subgroups in sometimes 
slightly different ways by different researchers.  Kuhlmann et al. have recently 
proposed a single system aimed at unifying these scales for ease of comparison 
across patients and studies (Kuhlmann et al., 2017). This scale varies across the 
amount of macrophage/microglia activity (active, mixed, or inactive) within the 
lesion and whether the lesion is demyelinating or post-demyelinating (Kuhlmann 
et al., 2017). Active lesions can contain reactive microglia/macrophages, 
astrocytes, and T cells. They are more commonly found in RRMS patients and 
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decrease with length of disease (Kuhlmann et al., 2017). Mixed active lesions 
have an outer border of activated microglia/macrophages and are more common 
in patients with longer disease duration and/or progressive types of MS 
(Kuhlmann et al., 2017). Inactive lesions have few microglia or T cells but may 
haven axonal damage or loss, and an astrocytic glial scar; these lesions are 
found in even longer duration of disease patients and progressive types of MS 
(Kuhlmann et al., 2017). Demyelinating lesions are characterized by a lack of 
myelin debris whereas post-demyelinating lesions do have debris; either state 
can be present with any inflammatory activity state (Kuhlmann et al., 2017). 
Lesion location appears to be associated with spontaneous remyelination; 
periventricular lesions have less remyelination than subcortical white matter 
lesions (Lassmann, 2013). Remyelination is less common in lesions of patients 
with longer disease duration (Stangel et al., 2017).  
 Limited data exists on KLK6 expression in specific cell types in MS brain, 
as well as between subtypes of lesions and across sub-classifications of the 
disease. The scope of execution on these tasks within this work was limited 
based on availability of postmortem MS patient brain tissue and number of lesion 
present within tissue obtained. Chapter four of this work focuses on the 
characterization of KLK6 expression in human postmortem tissue. Existing RNA 
sequencing information databases containing normal adult human tissue 
samples from various regions of the body were examined to determine KLK6 
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expression relative to the CNS and amongst other serine hydrolases.  
Postmortem MS patient brain lesions in subcortical white matter were examined 
for KLK6 expression using immunohistochemistry after immunocytochemical 
validation of the antibody to detect the human KLK6 protein. 
 
b) Methods 
i. Analysis of Adult Human Tissue Expression of KLK6 
 The Genotype-Tissue Expression (GTEx) Consortium database profiles 
gene expression by RNA sequencing across 449 adult human donors, within 42 
distinct biological tissues spanning the subregions of the brain and body 
(Consortium et al., 2017). The GTEx dataset (http://www.gtexportal.org) was 
utilized to examine the distribution and expression level of two-hundred and 
thirty-two serine hydrolases. A heat map was generated to demonstrate 
expression levels of the top 50 serine hydrolases (y-axis) at the genetic level that 
are enriched in brain compared to other tissues (x-axis). The scale (4 to -4) 
reflects a weighted average expression across tissues, where 4 (dark red) equals 
a 16-fold (24) increase in expression and -4 (dark blue) is a 16-fold decrease in 
expression. Additionally, a transcripts per million (tpm) graph was generated to 
illustrate and compare KLK6 expression levels in different subregions of the brain 
and body across multiple subjects. 
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ii. Validation of Human KLK6 Antibody by Immunocytochemistry 
 To determine specificity of KLK6-directed human antibodies, Chinese 
hamster ovary cells were transfected with full length human KLK6 (NM_002774) 
C-terminally tagged with myc and FLAG in the pCMV6-Entry plasmid (Origene 
RC218647) using Lipofectamine 2000 (Thermofisher Scientific).  For each 
treatment condition (Naïve, Non-template control transfected, KLK6 transfected), 
at least 6 ninety-six wells were run. Following transfection, cells were fixed using 
4% paraformaldehyde. Immunocytochemical staining was then done. Briefly, 
cells were permeabilized for 15 minutes with 0.5% triton-X-100, and then blocked 
for 1 hour in 10% normal donkey serum (Jackson ImmunoResearch) in PBS. 
Primary antibodies were incubated at 4 degree Celsius for 24 hours (Table 7).  
Then, samples were rinsed with PBS, incubated in donkey host species 
secondary antibodies with 568, Cy3, or 647-conjugated fluorophores 
(Thermofisher Scientific or Jackson ImmunoResearch) for 2 hours, and then 
counterstained with DAPI (Thermofisher Scientific). Full wells were imaged using 
a CellDiscoverer7 (Zeiss).  
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iii. Multiple Sclerosis Patient Tissue 
 Formalin-fixed, post-mortem human brain tissue was obtained from the 
Rocky Mountain Multiple Sclerosis Center Tissue Bank and National Multiple 
Sclerosis Society (Table 6). Tissue was blocked and processed to paraffin wax 
using a VIP6 Tissue Processor (Sakura), and sectioned at 5μm thickness using a 
microtome (Leica RM2145).  
 
iv. Immunohistochemistry 
 Sections were hydrated from paraffin wax using xylene, and gradient 
ethanol solutions to water. Citrate antigen retrieval (Biogenex) was performed in 
a pressurized decloaking chamber (BioCare Medical) for 30 seconds at 120 
degrees Celsius, then 10 seconds at 84.5 degrees Celsius. Afterwards, sections 
were stained using fluorescent immunohistochemistry. Briefly, sections were 
incubated with 0.5% tritonX-100 for 15 minutes, then with 10% normal serum of 
secondary antibody host species for 20 minutes, then primary antibody for ~48 
hours at 4 degree Celsius (Table 7). After PBS washes, secondary antibodies 
(AlexaFluor, Thermofisher Scientific) directed against the primary antibody host 
species were applied for 1.5 hours, and then counterstained with DAPI 
(Thermofisher Scientific). Sections were imaged using a Zeiss Axioscan Z1 
microscope and qualitatively examined. 
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c) Results 
 Two hundred and thirty-two serine hydrolases were profiled to determine 
those that are enriched in brain compared to peripheral tissues using the GTEx 
RNA sequencing database of adult human post-mortem tissue. KLK6 was 
determined to be the top serine hydrolase in that it has the highest expression in 
the largest number of CNS tissues compared to peripheral tissues (Figure 13A). 
The GTEx database was also used to visualize expression levels of KLK6 in 
transcripts per million across CNS and peripheral tissues in post-mortem adult 
human tissue. KLK6 expression was shown to be elevated in brain, spinal cord, 
and epithelia of peripheral tissues such as skin, esophagus, and reproductive 
organs (Figure 13B). Other kallikrein family members (KLK7, KLK5, KLK8, 
KLK10, KLK14) were also found in the top 50 serine hydrolases with enriched 
brain expression compared to peripheral tissue expression (Figure 13A). 
 To study KLK6 at the protein level, an antibody reactive to human 
kallikrein 6 was validated using immunocytochemistry following transient 
transfection of CHO cells with lipofectamine and a FLAG-conjugated vector 
containing the full-length human KLK6 gene. FLAG (Figure 14, red) and KLK6 
(Figure 14, green) co-localized using the human KLK6 abcam ab191281 
antibody (Figure 14, Merge). No stain was apparent from either antibody with a 
non-transfected control (NTC) cell cohort (Figure 14). 
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 Formalin-fixed post-mortem brain tissue was obtained from patients with a 
variety of MS subtypes for immunohistochemical analysis of KLK6 expression 
(Table 6), including PPMS, SPMS, and RRMS. White matter plaques were 
visible in the majority of samples across the subclassifications using an antibody 
to MBP. In general, most plaques were located in rostral telencephalic 
subcortical white matter and/or in close proximity to the ventricular system 
(example, Figure 15A-B). Cellular KLK6 staining was noted within several 
plaques, but absent in others. Images from a SPMS patient demonstrate two 
adjacent plaques [absence of MBP stain (red)], where the plaques have different 
levels of KLK6 (green) protein expression (Figure 15C). KLK6 staining was 
found in nearly all of the cases studied, regardless of MS behavioral 
subclassification. Aside from heterogeneous localization of KLK6 in plaques, 
cellular KLK6 staining was found in some cortical regions across MS 
subclassifications. In some instances cellular KLK6 staining was also found close 
to ventricular spaces even in the absence of MBP-negative plaques. The majority 
of KLK6 cells across all cases and brain regions exhibited a hypertrophied 
stellate morphology. To investigate cell type classification of staining given this 
profile, immunohistochemical co-labeling was done with astrocyte marker GFAP 
and microglia/macrophage marker Iba1. It was confirmed that the majority of 
KLK6 staining co-localized with astrocytic marker GFAP across the cases and 
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regions of the brain (Figure 15D-E). In contrast, cellular KLK6 staining did not 
co-localize with microglial marker Iba1 (Figure 15F-G). 
 
d) Discussion 
 Previous reports indicate that KLK6 gene expression is restricted to 
oligodendrocytes versus other major cell types in rodent and human brain such 
as neurons, microglia, and astrocytes (Zhang et al., 2014; Zhang et al., 2016). 
However, elevated levels of KLK6 protein have been identified in patients with 
MS, a CNS autoimmune disease that results in deterioration of myelin, and thus, 
the oligodendrocytes whose processes myelinate axons. Several studies have 
been done using MS patient biological fluids, such as CSF or serum. Specifically, 
MS patients showed higher KLK6 levels in CSF compared to controls (Hebb et 
al., 2010). Active KLK6 has also been found to be increased in RRMS patient 
CSF compared to controls (Bando et al., 2018). SPMS patient serum has been 
demonstrated to contain higher KLK6 than control patients (Scarisbrick et al., 
2008). High expression in CSF and serum could indicate that KLK6 is being 
cleared from the brain via dural venous sinuses and into the bloodstream. Still, it 
is unclear why KLK6 is elevated in MS brain, CSF or blood products. Data 
presented in this work using the GTEx database illustrates that KLK6 is normally 
enriched in the CNS compared to peripheral tissues in adult humans, and has 
the distinction of being the most abundant serine hydrolase in the CNS. The 
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enrichment of KLK6 in CNS compared to peripheral tissues also makes it an 
attractive therapeutic target for neurological disease in that it might be expected 
to have less off-target side effects. Because KLK6 is found to be elevated in MS 
patients compared to disease, a potential therapeutic avenue might be to lower 
KLK6 levels in MS. However, further characterization is needed to understand 
KLK6 expression in normal and MS brain. 
 Limited work has been done to characterize overall KLK6 expression at 
the protein level in human tissues. It has been shown that besides brain, 
peripheral nerves, choroid plexus and other glandular epithelia related tissue has 
high protein expression of KLK6 (Petraki et al., 2001). These findings appear in 
line with GTEx gene expression KLK6 dataset results. 
 In MS brain, KLK6 has been shown to be associated with plaques using 
immunohistochemistry (Scarisbrick et al., 2002). Here I have shown that KLK6 is 
not expressed equally in all plaques in MS brain tissue. Further, that its 
expression does not correspond to only a particular subclassification of MS such 
as SPMS or RRMS. In addition, cellular KLK6 staining can also be seen close to 
the ventricular system or in cortical regions despite the absence of plaques. 
 Based on the heterogeneous pattern within MS plaques, it seemed likely 
that KLK6 staining might be related to cellular composition of the plaque and 
whether active, mixed, or inactive state. MS plaque activity status is weighted on 
involvement of inflammatory cells, but particularly microglia/macrophages 
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(Kuhlmann et al., 2017). Additionally, there is some evidence that KLK6 is 
present in activated astrocytes in multiple neurological indications such as spinal 
cord injury, glioblastoma multiforme, and MS (Scarisbrick et al., 2012a). 
 I found that that cells immunoreactive for KLK6 in the MS cases tested 
were not likely to be macrophages or microglia due to lack of co-localization with 
Iba1. Instead, many KLK6 positive cells in the MS patient brains (in plaques and 
beyond) tested co-localized with astrocytic marker GFAP. Further, their stellate 
and hypertrophied morphology suggested their status as reactive astrocytes. The 
high correspondence of KLK6 to GFAP-positive cells makes it appear that very 
few KLK6-positive cells could also be oligodendrocytes. 
 Despite this, there may still be a connection between KLK6 expression 
and oligodendrocyte biology that include astrocytes. Astrocytes are influential in 
oligodendrocyte maturation and myelination. Astrocytes secrete factors such as 
PDGF, bFGF2, and LIF that promote oligodendrocyte maturation and myelination 
(Domingues et al., 2016). Additionally, oligodendrocytes primarily obtain lipids to 
synthesize myelin from astrocyte lipid synthesis (Camargo et al., 2017). 
Astrocytes can also negatively regulate oligodendrocyte maturation and 
myelination through mechanisms such as secretion of tenascin C, bone 
morphogenetic proteins, hyaluronan, and ET-1 (Silver and Miller, 2004; 
Domingues et al., 2016). These latter types of mechanisms are used by 
astrocytes involved in glial scar formation, which is important in isolating damage 
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one might see in spinal cord injury or in restoring blood-brain barrier breaches 
(Silver and Miller, 2004; Domingues et al., 2016). Also reflecting their dual nature 
and importance in control of regulation of processes, astrocytes can secrete pro-
inflammatory or anti-inflammatory factors to influence microglia/macrophage 
activity (Poutiainen et al., 2016). It has recently been shown that astrocytes are 
able to phagocytose myelin debris using receptor-mediated endocytosis (Ponath 
et al., 2017). The precise roles in which astrocytes can impact neurological 
disease such as MS are unclear. However, recent work from multiple disease 
areas has highlighted the need to understand the role of astrocytes in neurologic 
disease and the potential of this work to lead to new therapeutic treatments 
(Rostami et al., 2017; Hirase and Koizumi, 2018; Ponath et al., 2018). Live 
imaging methods are in development which could help clarify the role of 
astrocytes in MS (Poutiainen et al., 2016). 
 It has been previously reported that exogenous application of KLK6 on to 
cultured astrocytes results in a hypertrophied, stellate shape and thus, 
astrogliosis (Scarisbrick et al., 2012a). This suggests that in addition to 
oligodendrocytes, astrocytes are also responsive to KLK6. Taken together with 
the genetic evidence that KLK6 is found in oligodendrocytes and negatively 
associated with maturation, and that it is also a secreted protein which is found 
on astrocytes, this may suggest that oligodendrocytes regulate astrocytes via 
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KLK6 to then regulate maturation of oligodendrocytes/myelination by 
oligodendrocytes.  
 Further study is warranted to access the relationship between high KLK6 
mRNA expression in oligodendrocytes, and protein staining that associates KLK6 
immunoreactivity with GFAP-positive astrocytes.  This study demonstrated that 
the antibody used is reactive to human KLK6, ruling out a potential technical 
explanation. Another explanation could be that genetic expression was assessed 
in previous cell profiling experiments only during basal state, and that activated 
astrocytes do express high levels of KLK6. Thirdly, it may be that 
oligodendrocytes regulate their development by modulating astrocyte signaling 
with KLK6, as proposed above.  
 An additional consideration warranting further research is that it is unlikely 
that all KLK6 represented by immunohistochemical staining is all enzymatically 
active. It is unknown how protein expression levels of KLK6 correlate with KLK6 
enzymatic activity. Methods do not currently exist to profile enzymatic activity at 
the level of individual cells in human post-mortem tissue.  
 Due to the limited availability of control tissue processed in a similar 
manner as MS cases and limited clinical information on patients, comparisons of 
KLK6 expression across MS and control brain were not described. However, this 
should be a focus in future studies. Since KLK6 appears to be present in various 
diseases with reactive astrocytes, it might be that all reactive astrocytes stain for 
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KLK6, which would include the increase in astrogliosis that occurs with age 
(Santoro et al., 2018). Additional work should be done using a larger set of 
plaques of different activity stages from a range of MS patients to confirm a 
relationship between KLK6 expression and activity level within plaque. 
 In summary, expression of KLK6 is enriched in the adult human brain 
compared to peripheral organs and is the most highly expressed serine 
hydrolase in the CNS. Heterogeneous expression of KLK6 is found in MS 
plaques and seems more dependent on the activity state of plaques rather than 
subclassification of MS disease. However, KLK6 is also found outside of plaque 
regions defined by lack of MBP staining.  KLK6 co-localizes with GFAP-positive 
cells, or astrocytes in MS brain. This suggests a role of KLK6 in astrocyte and 
oligodendrocyte biology. The consequences of this are relevant for 
understanding the potential of therapeutic efficacy in MS patients with a KLK6 or 
KLK6 pathway inhibitor treatment. Further study is needed to understand the 
relationship between KLK6, astrocytes, oligodendrocytes, and MS. 
  
130 
 
 
 
RMMSC# Sample Type Sex Age PMI (hours) Slice 
561 PPMS F 53 19 6 
566 PPMS F 67 22 6 
316 SPMS F 53 N 9 
471 SPMS F 74 24 6 
501 Progressive* M 63 9 6 
550 Progressive* M 42 5.5 6 
540 CSLT-MS M 60 18 8 
521 CSLT-MS F 69 10 7 
414 CSLT-MS M 79 N 7 
425 CSLT-MS F 75 12 6 
411 RRMS M 42 12 6 
477 RRMS F 66 15 5 
465 RRMS M 56 41 7 
526 RRMS M 61 20 6 
401 RRMS M 58 30 7 
C113 Control M 62 24 9 
CSLT-MS = Chronic-Severe-Long-term MS (description, not official subclassification); N = Not given; 
Progressive*= Progressive was described by the family but no medical record confirmation was obtained. 
Table 6.  Human Brain Tissue Information 
 
Table 7. Chapter 4 Antibody Information 
  
Full Name Short 
Name 
Vendor Catalog 
Code 
Host  
Species 
Tissue Tested 
Species 
FLAG tag, M2 
clone 
FLAG Sigma Aldrich F9291 Mouse Human 
Myelin Basic 
Protein 
MBP AbD Serotec MCA409S Rat Mouse, Human 
Kallikrein 6 KLK6 Abcam ab191281 Goat Human 
Glial Fibrillary 
Acidic Protein 
GFAP Dako North 
America 
Z0034 Rabbit Mouse, Human 
Ionized calcium-
binding adapter 
molecule 1 
Iba1 Wako 
Chemicals 
019-19741 Rabbit Mouse, Human 
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Figure 13. Expression of KLK6 in Adult Human Tissues 
 
 A large effort by the Genotype-Tissue Expression (GTEx) Consortium profiled 
gene expression by RNA sequencing across 449 adult human donors, within 42 
distinct biological tissues spanning the subregions of the brain and body 
(Consortium et al., 2017).  
A: The GTEx dataset was utilized to examine the distribution and expression 
level of two-hundred and thirty-two serine hydrolases. KLK6 was one of the 
highest expressed serine hydrolyses throughout the brain compared to peripheral 
tissues. This heat map demonstrates expression levels of the top 50 serine 
hydrolases (y-axis) at the genetic level that are enriched in brain compared to 
other tissues (x-axis). The scale (4 to -4) reflects a weighted average expression 
across tissues, where 4 (dark red) equals a 16-fold (24) increase in expression 
and -4 (dark blue) is a 16-fold decrease in expression. 
B: Localization of KLK6 expression is shown in transcripts per million (tpm) 
across multiple adult human tissues. Enriched expression is found in brain, spinal 
cord, and epithelia of other peripheral tissues including skin, esophagus, and 
reproductive organs. 
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Figure 14. Validation of KLK6 Antibody 
 
To determine specificity of KLK6-directed human antibodies, Chinese hamster 
ovary cells were transfected with human KLK6 (NM_002774) C-terminally tagged 
with myc and FLAG in the pCMV6-Entry plasmid. Representative images 
demonstrate immunocytochemical staining for FLAG (red) and KLK6 (green) co-
localized for the human KLK6 abcam ab191281 antibody (Merge, yellow). No 
stain was apparent from either antibody with a non-transfected control (NTC) cell 
cohort. 
 
FLAG = red, KLK6 = green, DAPI = blue. Scale bar = 200 µm. 
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Figure 15. Heterogeneous Expression of KLK6 in Multiple Sclerosis 
Plaques 
 
A-B: Location of MS plaques in telencephalic white matter near the corpus 
callosum and cingulum bundle is depicted using a coronal view of the rostral 
aspect of the brain. The yellow box outline in A demonstrates the area shown in 
B. The white box in B demonstrates the area shown in C. Post-mortem brain 
tissue was obtained from the Rocky Mountain Multiple Sclerosis Center and 
National Multiple Sclerosis Society. C: Two plaques (lack of red, MBP) present in 
post-mortem brain tissue from a secondary progressive multiple sclerosis patient 
(RMMSC 316) demonstrate different levels of expression of KLK6 (green), as 
shown by merge and separation of three channels (KLK6 = green, MBP = red, 
DAPI = blue).  Scale bar = 500 µm (C), 2000 µm (B). 
 
D-E: Several KLK6 and GFAP immunoreactive co-localized cells in a 
demyelinated area (MBP stain absent) near the lateral ventricle are shown in two 
images from secondary progressive multiple sclerosis patient brain.  
GFAP = green, KLK6 = red, MBP = purple, DAPI = blue. Scale bar = 50 µm. 
 
F-G: KLK6 does not co-localize with cells that are Iba1 immunoreactive in a 
demyelinated area (devoid of MBP stain) near the lateral ventricle in multiple 
sclerosis patient brain. Iba1 = green, KLK6 = red, MBP = purple, DAPI = blue. 
Scale bar = 50 µm. 
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CHAPTER FIVE 
Discussion and Future Directions 
a) Discussion 
 Several therapeutic treatments exist to address the neuroinflammatory 
aspects of MS that drive pathology in the disease. However, treatment is often of 
limited therapeutic effectiveness and many treatments are only directed at 
RRMS, a single subclassification of MS clinical presentation (Ransohoff et al., 
2015). No current FDA-approved treatments address repairing the damage 
secondary to this inflammation- the demyelinated axons which impede normal 
neuronal signal conduction through the central nervous system. One of the 
current ongoing areas of research in MS is how remyelination could be enabled 
and whether it could help alleviate symptoms of the disease. An ideal treatment 
for MS might address both aspects known to contribute to MS pathology: an anti-
inflammatory to limit damage to the myelin sheath and a promotor of 
remyelination to restore damage to myelin. This treatment paradigm might also 
expand the clinical subclassifications that can benefit from therapeutic treatment 
to include progressive forms of the disease. Progressive patients could benefit 
from remyelination as they are more likely to have lost endogenous myelin repair 
activities seen in RRMS patients and to have plaques without ongoing 
inflammation (Harlow et al., 2015). However, there may still be advanced 
progressive MS patients to which myelin repair treatment is not therapeutic. They 
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may need neuroregenerative agents to be restorative, due to neuronal cell loss 
as a consequence of previous, prolonged demyelination (Bradl and Lassmann, 
2009; Criste et al., 2014). 
 The myelin sheath surrounding neuron axons that becomes damaged in 
MS is composed of oligodendrocyte processes. Kallikrein 6 (KLK6) is a serine 
protease found upregulated in MS that has been characterized to be expressed 
mainly by oligodendrocytes under basal conditions. It is currently unknown 
whether this upregulation is a contributor to MS pathology or if it is part of a 
compensatory response upregulated to enhance efforts to establish 
remyelination around demyelinated regions. 
 Evidence for its role as a pathogenic agent includes the fact that myelin 
basic protein, a key structural protein in the CNS myelin sheath, is a substrate of 
the KLK6 enzyme which preferentially cleaves proteins with basic amino acid 
chains (Prassas et al., 2015). Evidence for that it is a part of normal 
oligodendrocyte biology includes the fact that KLK6 knockout mice exhibit 
decreased major myelin proteins (such as MBP) up to postnatal day 14 in spinal 
cord, although by adulthood the levels are similar to control (Murakami et al., 
2013). 
 The studies in this dissertation have been directed at elucidating the role 
of KLK6 in oligodendrocyte maturation and myelination. In addition, efforts are 
undertaken to further characterize KLK6 expression in human biological tissues 
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and in MS patient post-mortem brain tissue. The specific goal of this research is 
to address whether KLK6 inhibition could be beneficial in oligodendrocyte 
maturation and remyelination. The overarching goal driving this research is to 
identify potential mechanisms of remyelination that could be therapeutically 
relevant in MS. 
 In chapter two of this work, I show that KLK6 mRNA expression is at its 
highest point when MBP mRNA expression levels peak during maturation of 
OPCs to oligodendrocytes in an embryonic brain-based, neurosphere-derived, 
cell maturation assay. MBP is a gene expressed by mature oligodendrocytes. A 
marker of more mature oligodendrocytes, MOG, is shown to peak later in 
maturation compared to MBP and KLK6. Additionally, the application of 
exogenous KLK6 or a reported downstream KLK6 pathway mediator (PAR1-AP) 
on neural stem cell-derived OPCs decreases the number of MBP-positive cells 
per well and/or total length of MBP-positive cell processes. While this could 
indicate induction of cell death rather than a lack of maturation, I did not find 
evidence of increased cell death with KLK6 application. A study in the literature 
also indicates that although exogenous KLK6 can make OLs more susceptible to 
ATP excitotoxicity, it does not induce cell death on its own (Burda et al., 2013).  
 When a novel KLK6 inhibitor (KLK6i) identified during a virtual screen 
(Liang et al., 2012a) was applied to neural stem cell-derived OPCs, it was found 
that the KLK6i increased the number of oligodendrocytes and OPCs in culture 
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compared to control treatment. When KLK6i treatment was combined with a T3 
maturation agent, the mechanisms appeared to be synergistic; they increase the 
number of OLs and their total branch length more than either treatment alone. 
Thus, these findings suggest that KLK6 is a negative modulator of OL maturation 
and KLK6 inhibition is a positive modulator of OL maturation. Using RNAseq 
analysis, the combination treatment of KLK6i and T3 was found to upregulate 
several pathways of genes involved in cholesterol synthesis more significantly 
than either treatment alone. Because cholesterol synthesis is predominately 
accomplished by astrocytes in the CNS (Kiray et al., 2016; Camargo et al., 
2017), this implicates astrocytes in modulation of OL maturation via KLK6 
 Animal models of demyelination and remyelination have been helpful in 
understanding whether and how potential therapeutics will alter outcomes in 
human MS. FDA-approved anti-inflammatories natalizumab, glatiramer acetate 
previously showed efficacy in the EAE model (Baxter, 2007). There are currently 
no FDA-approved remyelination therapies for MS. Potential remyelination 
therapies like muscarinic 1 receptor antagonists have succeeded in cuprizone 
and lysolecithin animal models of demyelination, and look promising in human 
MS patients in the clinic (Deshmukh et al., 2013; Mei et al., 2014; Mei et al., 
2016; Green et al., 2017).  In chapter three of this work, I assess the potential of 
KLK6 inhibition to increase CNS myelination in vivo. KLK6i was delivered ICV in 
mice for 14 days post-demyelination with 0.2% cuprizone to measure the ability 
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of KLK6i to aid in remyelination. This model was chosen specifically because it 
tests the ability of the compound to promote remyelination rather than 
neuroinflammatory aspect of demyelination.  
 Samples from CSF, plasma, and cerebellum were all found to contain 
KLK6i after 14 days of infusion into the lateral ventricle at the anatomical level of 
the anterior horn. This demonstrates delivery of the inhibitor was ongoing at the 
end of the study and shows distribution of the inhibitor in brain tissue as well as 
in fluid compartments. The mammalian ventricular system where CSF is 
produced (by the choroid plexus and ependymal cells), circulates CSF based on 
blood pressure gradients (Mortazavi et al., 2014; Simon and Iliff, 2016; Stratchko 
et al., 2016). Humans produce ~500 µL of CSF per minute, changing over total 
CSF volume (approximately 150 mL) four times a day (Simon and Iliff, 2016). 
Mice produce 0.35 µL per minute, changing over total CSF volume (~30-40 µL), 
twelve times per day (Simon and Iliff, 2016). In humans, CSF travels from the 
lateral ventricle through the interventricular foramen of Monro to the third 
ventricle near the hypothalamus, then through the cerebral aqueduct of Sylvius to 
the fourth ventricle which is ventral to the cerebellum. It exits the fourth ventricle 
through either the foramen of Magendie or the foramina of Luschka to surround 
the CNS in the subarachnoid space (Mortazavi et al., 2014). CSF is then 
reabsorbed into the blood stream through arachnoid granulations and the dural 
venous system (Simon and Iliff, 2016; Stratchko et al., 2016). The anatomy of the 
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mouse ventricular system is similar to human, but mice lack a foramen of 
Magendie (Simon and Iliff, 2016; Snyder et al., 2018).  
 The cuprizone model of demyelination decreases myelin fiber density 
most notably in the corpus callosum, a large white matter tract which 
interconnects the cerebral hemispheres of the brain (Skripuletz et al., 2011). The 
corpus callosum is composed of several main anatomical regions; from rostral to 
caudal aspect they are the rostrum, genu, body, and splenium (Nieuwenhuys et 
al., 2008). Generally, the topography of the corpus callosum is such that the 
more rostral aspects are involved in connecting association areas of more rostral 
aspects of the cerebral cortex, such as frontal cortex. More caudal aspects of the 
corpus callosum, such as the splenium, are associated with more posterior 
aspects of the cerebral cortex, such as the occipital lobe (Nieuwenhuys et al., 
2008). Myelination of the corpus callosum is thought to occur from posterior 
aspect to anterior (Fabri et al., 2014). Studies with cuprizone have demonstrated 
regional differences in extent of corpus callosum demyelination and 
remyelination based on the rostrocaudal axis position (Blakemore and Franklin, 
2008; Steelman et al., 2012; Tagge et al., 2016).  The extent in which cuprizone 
reduces demyelination depends on a variety of factors related to experimental 
paradigm. Animals treated with 0.2% cuprizone for 6 weeks do not have overt 
changes in behavior (Skripuletz et al., 2011). It has been reported that cuprizone 
elicits changes in more complex behavior (e.g. slower wheel-running in wheels 
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with further spaced rungs), but this has not yet been replicated across multiple 
groups (Hibbits et al., 2009). Animals treated with 0.2% cuprizone for greater 
than 9 weeks start to exhibit seizures (Skripuletz et al., 2011; Lapato et al., 
2017). 
 The corpus callosum is anatomically close in proximity to the lateral 
ventricle. The cannulation of mice at the anterior horn of the lateral ventricle puts 
delivery of KLK6i close to the genu / anterior portion of the body of the corpus 
callosum. This is where analysis for remyelination was conducted using 
histological methods. Due to the sample processing for histology to assess 
myelination and due to the low number of subjects per group related to the 
complicated nature of the surgical manipulation, the corpus callosum and 
adjacent tissue were not directly measured for KLK6i. However, it is expected 
that KLK6i exposure would be highest at the site of delivery compared to distal 
sites (drug exposure was measured in cerebellum, where it was expected to be 
less concentrated) due to protein binding estimates of the compound. 
 Cuprizone/KLK6i treated animals demonstrated an increase in myelination 
of the corpus callosum by luxol fast blue staining compared to cuprizone/vehicle 
treated mice. This result was corroborated by a trend increase with mature 
oligodendrocyte marker CC1 in the same region. Further, KLK6i treatment 
reduced the amount of GFAP-positive astrocyte staining in the corpus callosum 
compared to the induction seen after cuprizone treatment.  
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 This work demonstrates that a novel small molecule inhibitor of KLK6 can 
increase OL maturation and increase corpus callosum remyelination after 
cuprizone demyelination. This is the first time a KLK6i has been tested in the 
cuprizone model of demyelination. This is also the first example of a small 
molecule KLK6i being used to induce remyelination in an in vivo model. This data 
builds on previous data that suggests KLK6i could be useful in treating MS. 
Previously, exogenous KLK6 had been shown to increase white matter pathology 
when injected in normal mouse spinal cords and to increase motor disability in a 
mouse EAE model (Burda et al., 2013; Yoon and Scarisbrick, 2016). 
Contrariwise, a KLK6 knockout mouse was shown to have delayed onset and 
decreased motor disability using an EAE model paradigm (Bando et al., 2018). 
Additionally, a KLK6-neutralizing antibody was shown to delay motor disability 
and severity of symptoms in an EAE mouse model (Blaber et al., 2004; Bando et 
al., 2018). A KLK6-neutralizing antibody has also been shown to reduce 
progressive MS-like pathology at 40 days post-induction of pathology in the 
TMEV model of progressive demyelination but this was not sustained at 180 
days post-induction (Scarisbrick et al., 2012b).  
 Thus, I have demonstrated that a small molecule KLK6i can aid in 
remyelination in a toxin based MS animal model while others have shown a 
KLK6i can limit pathology in immunologic-based MS animal models. These 
experiments which assess the impact of KLK6i from different angles have 
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demonstrated that KLK6 inhibitors may have the potential to be therapeutic in MS 
patients. The limited effectiveness in immune-based animal models of MS may 
reflect that KLK6i may have limited anti-inflammatory ability. However, it may 
also suggest that combination with an anti-inflammatory treatment is needed for 
this remyelination therapy to combat continuing damage to myelin by 
inflammation. Currently there are no FDA-approved therapeutic agents for MS 
that improve remyelination. In order to run effective clinical trials in the area of 
remyelination, more work is likely needed to detect remyelination at high 
resolution, potentially including the establishment of upstream biomarkers. 
 Similarly, more work is needed to understand KLK6 expression and 
function in human health and disease. In chapter four of this work, I demonstrate 
that KLK6 is one of the highest expressed serine hydrolases in the adult human 
CNS using the GTEx RNAseq database. It is also relatively selective for CNS 
expression compared to peripheral tissue expression, which could make it an 
attractive target for treating neurological diseases. However, this highlights the 
lack of complete understanding around what KLK6 does in the adult CNS. 
Further, are there consequences to lowering KLK6 beyond the amount in which it 
is elevated in a disease state? One limitation of this dataset is that it provides a 
general view of adult “non-diseased” human gene expression; individual 
demographics and clinical history of patients are not easily searchable to 
understand if KLK6 is higher in some individuals compared to others. It is also 
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possible that KLK6 has other roles besides negatively impacting oligodendrocyte 
maturation and myelination. Additionally, besides OLs, previous work has 
identified the presence of KLK6 in activated states of certain cell types such as T 
lymphocytes, macrophages and astrocytes (Blaber et al., 2004; Terayama et al., 
2005; Scarisbrick et al., 2011; Scarisbrick et al., 2012a). RNAseq data that 
determined KLK6 was exclusively expressed in OLs was done on cells in their 
basal state, which could be the reason this was not described in that dataset 
(Zhang et al., 2014; Zhang et al., 2016). 
 Limited work has been done to characterize KLK6 expression at the 
protein level in the human CNS. A single study has done an expansive 
investigation into KLK6 protein expression using tissues spanning throughout the 
whole body. The results of this work suggest that choroid plexus and glial cells in 
brain (no region specified, no co-localization done) had the most KLK6 out of all 
of the CNS by immunohistochemistry (Petraki et al., 2001). Outside of the CNS, 
peripheral nerves and organs with epithelia had high expression by 
immunohistochemistry (Petraki et al., 2001). Although cell resolution is not 
available with the GTEx dataset, the overall finding that brain and peripheral 
epithelial tissues are positive for KLK6 is corroborated across both studies.  
 In MS patients, KLK6 has been shown to be at higher levels than control 
in CSF (Hebb et al., 2010; Bando et al., 2018), serum (Scarisbrick et al., 2008), 
and brain (Scarisbrick et al., 2002). The data on KLK6 protein expression in brain 
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suggests that KLK6 is generally located within and around the borders of MS 
plaques in discrete cells, but the cell type was not directly identified through co-
labeling (Scarisbrick et al., 2002). 
 In chapter four of this work, I used immunohistochemistry to examine MS 
post-mortem brain tissue from several patients with different subclassifications of 
the disease to characterize what is known about MS KLK6 expression in more 
detail. The numbers of plaques in the tissue obtained were relatively sparse, but 
there were no overt differences in KLK6 expression across patients with different 
subclassifications of MS. It was found that individual MS plaques even within the 
same patient and same region of brain had differential expression of KLK6 by 
immunohistochemistry. This finding makes sense because MS plaques are 
heterogeneous in nature; different cell types, particularly immune cell types, are 
present in different types of MS plaques (Kuhlmann et al., 2017). There are 
several different categorization schemes for classifying MS plaques, but they all 
largely currently depend on microglia/macrophage/astrocytic/T cell infiltration and 
whether the plaque is post-myelinating (Kuhlmann et al., 2017).  
 Co-labeling of KLK6-positive cells with astrocytic marker GFAP and 
microglia/macrophage marker Iba1 elucidated that the majority of KLK6-positive 
cells in MS plaques were astrocytes. There were also examples of reactive 
astrocytes outside of clear MS plaques that were positive for KLK6. 
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 Another group has reported that astrocytes assume reactive, 
hypertrophied morphology upon treatment with exogenous KLK6 (Scarisbrick et 
al., 2012a). Further, they demonstrate that reactive astrocytes from a few 
neurological conditions can contain KLK6; a chronically active MS plaque is 
shown to contain KLK6 in reactive astrocytes (Scarisbrick et al., 2012a). 
Together, this data supports that astrocytes may play a role in KLK6 impact on 
OL maturation and myelination, but more work is needed to further understand 
this relationship. Further study of KLK6 in MS should profile KLK6 expression in 
a larger number of MS plaques scored for various levels of microglia and 
astrocyte activity, as well as myelination status. Since the majority of positive 
KLK6 staining appears to be in astrocytes, not OLs, it is possible that the 
elevation of KLK6 seen previously in the literature with MS patient samples is 
due to an increase in reactive astrogliosis compared to control patients. A 
limitation of many studies that profile KLK6 protein expression by 
immunohistochemistry, including this work, is that the activation status of KLK6 is 
unknown. A potential method to investigate expression levels and activity levels 
in histological samples might be to use click chemistry methods combined with 
immunohistochemistry. Bando et al. use an antibody that only labels the active 
form of KLK6 and find expression to be in OLs (Bando et al., 2018). Future 
studies should explore whether the KLK6 present in astrocytes is active KLK6 
and whether activated astrocytes all secrete KLK6. 
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 Notably, three different experiments across this dissertation connect 
astrocyte involvement to KLK6 signaling related to oligodendrocytes. First, an 
antibody to KLK6 stains reactive astrocytes in human MS patient brain tissue. 
Second, KLK6 inhibition lowers GFAP-positive astrocyte staining post-cuprizone 
withdrawal in mouse corpus callosum. Third, KLK6 inhibition combined with 
maturation agent T3 significantly increases several cholesterol biogenesis 
pathways compared to either treatment alone. Cholesterol in the brain largely 
comes from astrocytes (Ferris et al., 2017). Thus, putatively, it may be that KLK6 
inhibition increases astrocyte-related cholesterol synthesis which in turn 
enhances remyelination by oligodendrocytes. One limitation of this hypothesis is 
the decrease in astrocyte marker GFAP stain seen with KLK6 inhibition 
concurrent with a proposed increase in astrocyte cholesterol synthesis. It seems 
unlikely a decrease in number of astrocytes could increase cholesterol synthesis, 
if they are responsible for the cholesterol synthesis. It is also unlikely that 
astrocytes were removed from the site of remyelination because the literature 
has demonstrated that ablating astrocytes inhibits myelin debris cleanup after 
cuprizone and delays remyelination (Skripuletz et al., 2013).  
A possible explanation could be that the GFAP antibody is not detecting all 
astrocytes and that a different population of cholesterol-synthesizing astrocytes is 
increasing. Although GFAP was at one point thought to label all astrocytes, now 
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Aldh1L1 is considered the most inclusive marker (Zhang and Barres, 2010). In 
addition, multiple isoforms of GFAP exist. The antibody used for this study does 
not have information on the isoforms it detects. The literature suggests that 
different types of reactive astrocytes are selective for different GFAP isoforms 
(Kamphuis et al., 2014). It seems most likely that GFAP is a sensitive measure 
for reactive astrocytes, and the decrease in GFAP is due to dynamic regulation of 
intermediate filaments being restored to basal astrocyte state in response to 
KLK6 inhibition. It may also be that reactive astrocytes produce less cholesterol.  
In the literature, a study used alpha-synuclein peptide to cause human primary 
astrocytes in culture to exhibit morphological characteristics of reactivity. They 
found that these reactive astrocytes had higher levels of GFAP staining but had 
decreased levels of cholesterol in the membrane fraction of the homogenate 
compared to control treatment (Koob et al., 2010). More work is needed to 
determine if this is what happens with exogenous KLK6 application to astrocytes, 
and if the reverse occurs in response to KLK6 inhibition. 
 Astrocytes perform a variety of roles within the CNS: they maintain and 
regulate the environment by secreting growth factors, lactate, cholesterol, 
thrombospondins, and extracellular matrix proteins; they help form the blood-
brain barrier which protects the brain from peripheral insults; they can also 
secrete cytokines and chemokines to which can then direct downstream 
immunological cascades (Kiray et al., 2016; Li et al., 2016). Generally, there are 
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two main types of astrocytes have been described in the brain which are largely 
defined based on morphology and location (Barres, 2008). Protoplasmic 
astrocytes are large with many branches and are located in gray matter (Li et al., 
2016). Fibrous astrocytes are smaller with fewer processes, but those processes 
are longer in length (Li et al., 2016). Fibrous astrocytes are located in white 
matter (Li et al., 2016). It is currently not well-understood whether astrocytes are 
incredibly dynamic, performing a variety of functions, or whether specific types of 
astrocytes, which we have been unable to clearly define, have unique capabilities 
and functions. Continued work is needed to further understand astrocytes 
heterogeneity and function (Zhang and Barres, 2010). 
 Astrocytes influence myelination in several known ways. They promote 
OPC proliferation and development through secretion of growth factors PDGF 
and bFGF (Kiray et al., 2016). Their secretion of growth factors leukemia 
inhibitory factor and ciliary neurotrophic factor helps promote maturation and 
survival of OLs (Kiray et al., 2016; Li et al., 2016). Other factors they secrete 
such as bone morphogenetic proteins, interleukin 6, or hyaluronan inhibit OPC 
maturation and/or OL maturation and myelination (Li et al., 2016). 
 Reactive astrocytes are present in several neurologic diseases, including 
MS (Li et al., 2016; Hirase and Koizumi, 2018; Ponath et al., 2018). However, 
relatively little is known about whether astrocytes are more part of compensatory 
mediation as a result of disease or contributors to disease pathology. In MS, 
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reactive astrocytes can perpetuate pro-inflammatory signaling which contributes 
to demyelination (Li et al., 2016; Ponath et al., 2018). They can also form a glial 
scar to prevent peripheral cell invaders from further damaging the CNS (Li et al., 
2016; Ponath et al., 2018). Further work to understand and regulate astrocyte 
diversity and function may help development of therapeutic interventions for MS 
and other neurologic diseases. 
 In contrast to the KLK6i used in this work, a previously untested brain 
penetrant PAR1 inhibitor did not demonstrate increased OL maturation in vitro or 
increased remyelination over spontaneous remyelination two weeks post-
withdrawal of cuprizone in a mouse model of corpus callosum demyelination. The 
PAR1 pathway is expected to be downstream of KLK6 (Burda et al., 2013). It 
was thought that PAR1 inhibition could be another method to test KLK6 inhibition 
should properties of the KLK6 inhibitor be unfavorable to testing. The PAR1 
inhibitor selected for the studies in this dissertation had good brain exposure and 
target selectivity, which was ideal for in vivo testing and differentiated it from 
other commercially-available PAR1 inhibitors. Results in the literature with 
genetic PAR1 knockout models suggest that the reason for failure of this 
compound in both the in vitro and in vivo assays is due to poor drug properties 
(Burda et al., 2013), such as protein binding. Additionally, a different PAR1 
inhibitor (SCH79797) has been shown to increase OL maturation in primary 
OPCs (Yoon et al., 2015). The SCH79797 compound was not selected for study 
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in this dissertation because it was determined unlikely to be brain penetrant 
(based on structure). While the two compounds have very different chemical 
structures, they have similar IC50 values and are both expected to be selective for 
PAR1 compared to other PARs. Future work should be done to confirm efficacy 
of the two compounds head-to-head in an OPC maturation assay. Additionally, 
brain penetrance, receptor binding selectivity, and potency should be confirmed 
experimentally.  Although the compounds were assessed based on available 
information, they were not compared head-to-head. This act could have provided 
additional information. One explanation for the discrepancy between compounds 
could be related to compound potency and the mechanism of PAR1 modulation. 
PAR1 signaling is expected to be mediated through downstream calcium ion 
activity (Burda et al., 2013). It is known that differential patterns of calcium ion 
signaling elicit different effects on oligodendrocytes and myelination (Baraban et 
al., 2018). Perhaps one compound has higher potency and was administered in a 
manner that created an alternative calcium signaling pattern that was not 
conducive to OPC maturation or myelination by OLs. Another explanation could 
be that although the compounds are both selective for PAR1, one is more 
selective than the other. 
 At the time the in vitro OPC maturation assay work was done with the 
PAR1 inhibitor, it was unclear whether the in vitro assay results would directly 
predict remyelination efficacy in vivo. Based on the two compounds profiled in 
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this work, it appears that the in vitro OPC maturation assay was predictive for 
determining remyelination efficacy in vivo following cuprizone demyelination. This 
may or may not be true with different mechanisms of OL maturation due to the 
limitations of the in vitro assay, which does not include all cell types. 
 
b) Future Directions 
i. Further Development of KLK6 Inhibitors for Remyelination 
 While the KLK6 inhibitor used in this work was able to inhibit KLK6, it was 
not readily brain penetrant. Future small molecule KLK6 inhibitors should be 
developed with increased brain penetrance when administered using a peripheral 
route of administration. This would avoid complicated delivery techniques, such 
as invasive surgery, to allow the drug to be useful as a CNS remyelination 
therapeutic in humans. Specificity for KLK6 should also be tested at escalating 
concentrations compared to other kallikrein family members or other serine 
proteases due to similarity of their protein cleavage mechanism (Di Cera, 2009). 
Additionally, compounds will need to be assessed for exposure and adverse 
events throughout the body during acute and chronic administration paradigms. 
Specific areas in the body where adverse events might be expected are in 
reproductive tissue and epithelium of other various organs (e.g. esophagus), as 
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moderate levels of KLK6 expression have been detected in these regions 
(Petraki et al., 2001).   
 Therapies combining anti-inflammatory and remyelination properties are 
expected to be the most effective treatment for MS due to the inflammation-
directed damage of myelin and the decreasing propensity of remyelination over 
time in the disease (Stangel et al., 2017).  Thus, groups in both the preclinical 
and clinical space are beginning to test potential remyelination therapies 
alongside anti-inflammatory treatments. For example, benztropine, a muscarinic 
antagonist shown to increase myelination, was combined with anti-
inflammatories and this combination was found to reduce behavioral 
manifestations of pathology in an EAE (PLP129-151) preclinical model more than 
either agent on its own (Deshmukh et al., 2013). Further, an ongoing clinical trial 
with a myelination-promoting LINGO-1 antagonist is testing the antagonist in 
combination with anti-inflammatory treatments without a LINGO-1 only treatment 
arm (ClinicalTrials.gov  NCT03222973). Similarly, KLK6 inhibitors should be 
tested in combination with anti-inflammatory agents in progressive animal models 
such as the TMEV model of demyelination to see if combined therapy is more 
effective in enhancing remyelination and decreasing disease progression than 
either alone.  
 In order to more effectively measure remyelination in human clinical trials 
to evaluate therapeutics, further development is needed to identify or enhance 
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clinical measures or biomarkers indicative of remyelination. Currently, MR 
methods of the brain and EVP of optic nerve are our best measurements 
available (Kilsdonk et al., 2016; Cadavid et al., 2017; Green et al., 2017). 
Increased resolution of clinical measures of remyelination would provide more 
precise measurements of clinical outcomes. For example, clinical measurements 
could be based on molecular and cellular pathways that manifest earlier than 
end-stage behavior consequences of decreased myelination. This could also 
lead to a reduction in length of clinical trials. 
 
ii. The Impact of Remyelination in Disease 
 There is some debate about whether remyelination therapies will be able 
to significantly ameliorate disease pathology in neurological diseases with 
demyelination. Some argue that remyelination is not the same as original 
myelination, particularly focusing on that it is “thinner” (Prineas and Connell, 
1979). Others say that this is an artifact of time-dependence when measuring 
myelin thickness (Powers et al., 2013). In either case, the main concern is that 
thinner remyelination is not optimally performing compared to the original myelin, 
for whatever length of time for which it is thinner. 
 Regarding whether remyelination can ever reach original myelin thickness 
levels, studies in zebrafish suggest that remyelination can be achieved at optimal 
original myelin thickness in younger fish, but not in older fish (Munzel et al., 
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2014). This suggests that there may be factors changing in aging that may be 
useful to target to enhance remyelination so that it can be as thick as the original 
myelin. Regarding the properties of thinner remyelination, a recent longitudinal 
study in a small number of dogs and cats indicates that thinner remyelination 
after demyelination persists over years and is adequately functional compared to 
original myelin (Duncan et al., 2017). More longitudinal studies combining 
functional outcomes as well as structural are needed to confirm whether thinner 
remyelination has functional limitations compared to original myelination or if it is 
perfectly adequate. If it is determined that thinner myelin is actually functionally 
limited in conduction capacity, research should be pursued to increase the speed 
in which optimally-functioning thicker myelin can be re-created. 
 While remyelination therapies aim to restore myelin in diseases in which 
they have been lost, there may be some types of patients where remyelination is 
not possible.  For example, remyelination therapy would not be effective in 
patients who no longer have neuronal axons/neurons that can be myelinated, as 
can occur in progressive MS patients (Criste et al., 2014).  Further, it may be that 
remyelination therapies have synergistic effects when combined with a sustained 
propensity to remyelinate, such as was seen in vitro with a KLK6 inhibitor and T3 
maturation agent. This may suggest that a remyelination therapy would be more 
effective in patients such as RRMS patients that still have remyelination capacity 
compared to progressive patients with diminished remyelination capacity. Thus, 
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perhaps remyelination therapy would be restorative in RRMS, but would merely 
put the brakes on further deterioration in progressive forms of MS. This type of 
treatment would still be very impactful for progressive patients. 
 Historically, clinical demonstration of remyelination in response to 
treatment has been limited to MR imaging which lacks ideal resolution. Recently, 
techniques to clinically demonstrate remyelination have expanded to include EVP 
analysis of optic nerve myelination (Kilsdonk et al., 2016; Cadavid et al., 2017; 
Green et al., 2017). EVPs may currently be the most promising measure to 
rapidly test remyelination efficacy in clinical trials (Cadavid et al., 2017; Green et 
al., 2017). Better clinical imaging methods are needed in order to better assess 
remyelination potential in live humans throughout the brain and spinal cord 
(Kilsdonk et al., 2016). 
 Identifying mechanisms in which CNS myelination or remyelination could 
be therapeutically enhanced could be beneficial to several disorders in which 
CNS demyelination is present. The most obvious example is MS, a 
demyelinating disease. However, there is some evidence for decreased 
myelination in developmental disorders. Patients with autistic disorders may also 
have less myelination than normally developing peers (Deoni et al., 2015) and/or 
auto-antibodies to myelin proteins (Gonzalez-Gronow et al., 2015). Several 
disorders involving psychosis, such as schizophrenia, are reported to exhibit 
aberrant myelination in frontal/prefrontal cortical regions of the brain (Mighdoll et 
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al., 2015). Further, perhaps enhancement of myelination might be helpful in 
boosting normal cognition and reducing dementia generally associated with 
myelin loss in aging (Peters et al., 1996; Rivera et al., 2016). 
 
iii. Aberrant KLK6 Signaling in Other Neurological Diseases 
 Dysregulation of KLK6 has been implicated in several other 
neurodegenerative diseases besides MS including: Alzheimer’s disease (Sun et 
al., 2017), Parkinsonism disorders (Iwata et al., 2003; Tatebe et al., 2010; 
Spencer et al., 2013; Spencer et al., 2015; Pampalakis et al., 2017), and spinal 
cord injury (Murakami et al., 2013; Radulovic et al., 2013). KLK6 expression has 
also been shown to be correlated with low survival rate in glioblastoma 
multiforme patients; it is expressed at higher levels in grade IV compared to 
grade III gliomas (Drucker et al., 2015).  
 Although direct KLK6 dysregulation has not been identified in all disorders 
with aberrant myelination, if KLK6 inhibition can increase production of 
oligodendrocytes, these disorders might also be able to benefit from treatment.  
 
iv. KLK6 Modulation in the Peripheral Nervous System 
 While the central and peripheral nervous systems both myelinate axons 
the ways in which this is accomplished are not completely the same. However, it 
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is reasonable to entertain whether KLK6 has a role in peripheral myelination 
and/or Schwann cell maturation because KLK6 has a role in oligodendrocyte 
maturation and CNS myelination. There is not currently much known about the 
role of KLK6 in the peripheral nervous system. The literature has reported that 
peripheral nerves demonstrate expression of KLK6 by immunohistochemistry 
(Petraki et al., 2001). Still, the presence of a molecule is not necessarily 
indicative of a similar function across peripheral and central nervous systems. 
For example, neuregulin 1 has varying importance and roles in peripheral 
myelination and CNS myelination (Taveggia et al., 2008; Feltri et al., 2016).  
Further study is warranted to confirm presence and determine involvement of 
KLK6 in the myelination of peripheral nerves. 
 
v. KLK6 Modulation in Non-Neurological Diseases 
 KLK6 has been recently shown to be upregulated in prostate cancer, in 
addition to other kallikrein family members (Oikonomopoulou et al., 2010; Bayani 
and Diamandis, 2011). It has also been shown to be increased in ovarian cancer 
(Korbakis et al., 2017). Currently, KLK6 is being proposed or used as a 
biomarker in these cancers. The mechanism that leads to upregulation in these 
cancers is unknown. One potential explanation for increased KLK6 expression is 
that KLK6 has been shown to be upregulated by increases in estrogen and 
progestins that are elevated in some cancers (Yousef et al., 1999). At the same 
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time, hormones elevated during pregnancy appear to decrease symptomatic 
relapses in MS (Miller et al., 2014). Levels of KLK6 have been shown to be high 
in general in MS, but have not been specifically examined in pregnant MS 
patients compared to non-pregnant MS patients. Learning more about the 
underlying mechanisms driving KLK6 elevation in one disease may be 
informative for other diseases. Additional work should be done to clarify the 
mechanism of KLK6 upregulation in reproductive organ cancers and whether 
peripheral treatment of epithelial cancers with high levels of KLK6 could be 
effectively treated with peripheral KLK6 inhibitors. 
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